> l \pThe Free Software Foundation B=PF0*8X@"1 Helvetica1Courier1Courier New1Courier New1 Helvetica$#,##0_);($#,##0)$#,##0_);[Red]($#,##0)$#,##0.00_);($#,##0.00)$#,##0.00_);[Red]($#,##0.00)**_($* #,##0_);_($* (#,##0);_($* ""_);_(@_)*)'_(* #,##0_);_(* (#,##0);_(* ""_);_(@_)5,2_($* #,##0.00_);_($* (#,##0.00);_($* ""??_);_(@_)2+/_(* #,##0.00_);_(* (#,##0.00);_(* ""??_);_(@_)2$#,##0.00;[Red]$#,##0.003$#,##0.00;[Red]($#,##0.00)4$#,##0;[Red]($#,##00)50.00%;[Red](0.00%)60%;[Red](0%)7#,##0.00;[Red](#,##0.00)8#,##0;[Red](#,##0) + ) , * Ј ~~ ؈ ~~#؈ ~~ ؈ ~~8#܈ ~~9#܈ ~~4#܈ ~~3#܈ ~~7#܈ ~~83ffff̙̙3f3fff3f3f33333f33&,JAZZ PHARMACEUTICALS PUBLIC LIM%Waterloo Road Dublin 4 IrelandU&
SIGNATURES&n<CONDENSED CONSOLIDATED BALANCE &b[CONDENSED CONSOLIDATED STATEMEN& CONDENSED CONSOLIDATED STAT (1)&CONDENSED CONSOLIDATED STAT (2)&ݸAdoption of New Accounting Stan&3 Cash and AvailableforSale Sec&3 Cash and AvailableforSale (1)4 Fair Value Measurement&`5 Derivative Instruments and He&5 Derivative Instruments an (1)&/5 Derivative Instruments an (2)&t@5 Derivative Instruments an (3)&0R5 Derivative Instruments an (4)c
6 Inventories&`q7 Goodwill and Intangible Asset&7 Goodwill and Intangible A (1)&h7 Goodwill and Intangible A (2)$8 Certain Balance Sheet Items$8 Certain Balance Sheet I (1)
9 Debt
Maturities11 Shareholders Equity!11 Shareholders Equity (1)&Accumulated Other Comprehensive&Z12 Net Income per Ordinary Shar&3,12 Net Income per Ordinary (1);13 RevenuesO13 Revenues (1)_13 Revenues (2)&
@
l %
dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??1!JAZZ PHARMACEUTICALS PUBLIC LIM
SIGNATURES!CONDENSED CONSOLIDATED BALANCE !CONDENSED CONSOLIDATED STATEMEN!CONDENSED CONSOLIDATED STAT (1)!CONDENSED CONSOLIDATED STAT (2)!Adoption of New Accounting Stan!3 Cash and AvailableforSale Sec!3 Cash and AvailableforSale (1)4 Fair Value Measurement!5 Derivative Instruments and He!5 Derivative Instruments an (1)!5 Derivative Instruments an (2)!5 Derivative Instruments an (3)!5 Derivative Instruments an (4)
6 Inventories!7 Goodwill and Intangible Asset!7 Goodwill and Intangible A (1)!7 Goodwill and Intangible A (2)8 Certain Balance Sheet Items8 Certain Balance Sheet I (1)9 Debt
Maturities11 Shareholders Equity11 Shareholders Equity (1)!Accumulated Other Comprehensive!12 Net Income per Ordinary Shar!12 Net Income per Ordinary (1)
13 Revenues13 Revenues (1)13 Revenues (2)!Contract Liabilities Deferred R14 ShareBased Compensation
Share OptionsRestricted Stock Units!Continued Emphasis on Research Continued Emphasis on Rese (1)Results of Operations
Revenues!Research and Development Expens!To continue to grow our businesContractual Obligations!Issuer Purchases of Equity Secu!Issuer Purchases of Equity (1)Base Rent Schedule!CompanyPlanGrant NoticeAgreemen!Additional TermsAcknowledgement!CompanyPlanRSUsAwardGrant Notic!Additional TermsAcknowledge (1)U }U}$}$ }}$
Jazz Pharmaceuticals plc10Q
11/06/2018( Waterloo Road, Dublin 4, Ireland
Large accelerated filer
?
Accelerated filer
?Nonaccelerated filer ?!Smaller reporting company ?
Emerging growth company ?$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/,~rfZNpth\4=PF0*8X>
@
l 65;
dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??1!JAZZ PHARMACEUTICALS PUBLIC LIM Waterloo Road Dublin 4 Ireland!CONDENSED CONSOLIDATED BALANCE !CONDENSED CONSOLIDATED STATEMEN!CONDENSED CONSOLIDATED STAT (1)!CONDENSED CONSOLIDATED STAT (2)!Adoption of New Accounting Stan!3 Cash and AvailableforSale Sec!3 Cash and AvailableforSale (1)4 Fair Value Measurement!5 Derivative Instruments and He!5 Derivative Instruments an (1)!5 Derivative Instruments an (2)!5 Derivative Instruments an (3)!5 Derivative Instruments an (4)
6 Inventories!7 Goodwill and Intangible Asset!7 Goodwill and Intangible A (1)!7 Goodwill and Intangible A (2)8 Certain Balance Sheet Items8 Certain Balance Sheet I (1)9 Debt
Maturities11 Shareholders Equity11 Shareholders Equity (1)!Accumulated Other Comprehensive!12 Net Income per Ordinary Shar!12 Net Income per Ordinary (1)
13 Revenues13 Revenues (1)13 Revenues (2)!Contract Liabilities Deferred R14 ShareBased Compensation
Share OptionsRestricted Stock Units!Continued Emphasis on Research Continued Emphasis on Rese (1)Results of Operations
Revenues!Research and Development Expens!To continue to grow our businesContractual Obligations!Issuer Purchases of Equity Secu!Issuer Purchases of Equity (1)Base Rent Schedule!CompanyPlanGrant NoticeAgreemen!Additional TermsAcknowledgement!CompanyPlanRSUsAwardGrant Notic!Additional TermsAcknowledge (1)U }y
}:}
6
Jazz Pharmaceuticals plc10Q
11/06/2018
SIGNATURES
Page&PART I  FINANCIAL INFORMATION
Item 1.
Financial Statements~
%Condensed Consolidated Balance Sheets~
% September 30, 2018 and December 31,~
,$Condensed Consolidated Statements of~
6.Income  Three and Nine Months Ended September30, 2018 and 2017,$Condensed Consolidated Statements of~
%Comprehensive Income  Three and Nine0(Months Ended September 30, 2018 and 2017,$Condensed Consolidated Statements of~
0(Cash Flows  Nine Months Ended September30, 2018 and 20171)Notes to Condensed Consolidated Financial~
StatementsItem 2.,$Management?s Discussion and Analysis~
n80of Financial Condition and Results of OperationsD*lpd@}2K"[Y7 !"#$%&'()*+,./012345 Item 3.0 (Quantitative and Qualitative Disclosures~
!!About Market Risk"""#Item 4.#Controls and Procedures~
#$$#%PART II  OTHER INFORMATION%&&&'Item 1.'Legal Proceedings~
'((()Item 1A.)Risk Factors~
)***+Item 2./+'Unregistered Sales of Equity Securities~
+v,,and Use of Proceeds.Item 6..Exhibits~
.z///0
SIGNATURES~
012$3____________________________14)Created by Morningstar Document Research.05(http://documentresearch.morningstar.com/0^mIlH=PF0*8X>
@255443300%%
l 7NX
dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??1!JAZZ PHARMACEUTICALS PUBLIC LIM Waterloo Road Dublin 4 Ireland
SIGNATURES!CONDENSED CONSOLIDATED STATEMEN!CONDENSED CONSOLIDATED STAT (1)!CONDENSED CONSOLIDATED STAT (2)!Adoption of New Accounting Stan!3 Cash and AvailableforSale Sec!3 Cash and AvailableforSale (1)4 Fair Value Measurement!5 Derivative Instruments and He!5 Derivative Instruments an (1)!5 Derivative Instruments an (2)!5 Derivative Instruments an (3)!5 Derivative Instruments an (4)
6 Inventories!7 Goodwill and Intangible Asset!7 Goodwill and Intangible A (1)!7 Goodwill and Intangible A (2)8 Certain Balance Sheet Items8 Certain Balance Sheet I (1)9 Debt
Maturities11 Shareholders Equity11 Shareholders Equity (1)!Accumulated Other Comprehensive!12 Net Income per Ordinary Shar!12 Net Income per Ordinary (1)
13 Revenues13 Revenues (1)13 Revenues (2)!Contract Liabilities Deferred R14 ShareBased Compensation
Share OptionsRestricted Stock Units!Continued Emphasis on Research Continued Emphasis on Rese (1)Results of Operations
Revenues!Research and Development Expens!To continue to grow our businesContractual Obligations!Issuer Purchases of Equity Secu!Issuer Purchases of Equity (1)Base Rent Schedule!CompanyPlanGrant NoticeAgreemen!Additional TermsAcknowledgement!CompanyPlanRSUsAwardGrant Notic!Additional TermsAcknowledge (1)U }2}$
7
Jazz Pharmaceuticals plc10Q
11/06/2018%CONDENSED CONSOLIDATED BALANCE SHEETS
September 30,
December 31,~
~
ASSETS
Current assets:
!Cash and cash equivalents~
*u~
ΏInvestments~
""~
b
.&Accounts receivable, net of allowances~
6~
Inventories~
~
Prepaid expenses~
Vj~
:jOther current assets~
P~
:Total current assets~
aY~
V;*"Property, plant and equipment, net~
~
a
Intangible assets, net~
F~
ԵGoodwill~
8~
F9 Deferred tax assets, net~
:K~
Deferred financing costs~
*~
w Other noncurrent assets~
k~
Total assets~
rN~
b8,$LIABILITIES AND SHAREHOLDERS? EQUITYCurrent liabilities:Accounts payable~
G~
Accrued liabilities~
~
!D%lymaUIl6;rV2jZ !"#$%&'()*+,./0123456) !Current portion of longterm debt~
~
vz !Income taxes payable~
!o!!~
!&Q!"Deferred revenue~
"\""~
""!#Total current liabilities~
###~
##%$Deferred revenue, noncurrent~
$ڪ$$~
$$,%$Longterm debt, less current portion~
%@_%%~
%F^%%&Deferred tax liabilities, net~
&&&~
&g&%'Other noncurrent liabilities~
'''~
'
'/('Commitments and contingencies (Note 10)(((()Shareholders? equity:)))*Ordinary shares~
***~
**'+Nonvoting euro deferred shares~
+++~
++",Capital redemption reserve~
,b,,~
,b,"Additional paidin capital~
B~~
!v,.$Accumulated other comprehensive loss~
...~
.f./Retained earnings~
/jD//~
/8/"0Total shareholders? equity~
0Ÿ00~
0&021*Total liabilities and shareholders? equity~
1rN11~
1b8123$4____________________________15)Created by Morningstar Document Research.06(http://documentresearch.morningstar.com/2 3r 0dYZ=PF0*8X>
@:G66554411110000////....,,,,++++****''''&&&&%%%%$$$$####""""!!!!
l 0Bs{
dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??1!JAZZ PHARMACEUTICALS PUBLIC LIM Waterloo Road Dublin 4 Ireland
SIGNATURES!CONDENSED CONSOLIDATED BALANCE !CONDENSED CONSOLIDATED STAT (1)!CONDENSED CONSOLIDATED STAT (2)!Adoption of New Accounting Stan!3 Cash and AvailableforSale Sec!3 Cash and AvailableforSale (1)4 Fair Value Measurement!5 Derivative Instruments and He!5 Derivative Instruments an (1)!5 Derivative Instruments an (2)!5 Derivative Instruments an (3)!5 Derivative Instruments an (4)
6 Inventories!7 Goodwill and Intangible Asset!7 Goodwill and Intangible A (1)!7 Goodwill and Intangible A (2)8 Certain Balance Sheet Items8 Certain Balance Sheet I (1)9 Debt
Maturities11 Shareholders Equity11 Shareholders Equity (1)!Accumulated Other Comprehensive!12 Net Income per Ordinary Shar!12 Net Income per Ordinary (1)
13 Revenues13 Revenues (1)13 Revenues (2)!Contract Liabilities Deferred R14 ShareBased Compensation
Share OptionsRestricted Stock Units!Continued Emphasis on Research Continued Emphasis on Rese (1)Results of Operations
Revenues!Research and Development Expens!To continue to grow our businesContractual Obligations!Issuer Purchases of Equity Secu!Issuer Purchases of Equity (1)Base Rent Schedule!CompanyPlanGrant NoticeAgreemen!Additional TermsAcknowledgement!CompanyPlanRSUsAwardGrant Notic!Additional TermsAcknowledge (1)U }6}$
0
Jazz Pharmaceuticals plc10Q
11/06/20183+CONDENSED CONSOLIDATED STATEMENTS OF INCOME
Three Months Ended
Nine Months Ended
September 30,
September 30,~
~
~
~
Revenues:
Product sales, net~
d~
~
nU~
}G'Royalties and contract revenues~
BA~
<~
~
Total revenues~
~
>#~
UV~
Z)HOperating expenses:
5Cost of product sales (excluding amortization~
:~
~
~
2/of intangible assets)+#Selling, general and administrative~
~
~
~
J{ Research and development~
b~
~
_
~
~%Intangible asset amortization~
6~
F~
.u ~
r
Impairment charges  ~
B
4,Acquired inprocess research and development ~
~
" Total operating expenses~
R ~
f~
<~
0Income from operations~
~
F~
^;~
֨Interest expense, net~
b~
"~
vc~
ڏForeign exchange loss~
2~
B~
~
q/'Loss on extinguishment and modification  ~
of debt.&Income before income tax provision and~
6R
~
:~
7~
BDlsg[OC0~kJ,!t !"#$%&'()*+,./# equity in loss of investees!Income tax provision~
!R.!!~
!^!!~
! *!!~
!
!#"Equity in loss of investees~
"""~
"F""~
" B""~
"
"#
Net income~
# ##~
###~
# 2##~
#
f#$$$$$$ $$
&%Net income per ordinary share:%%%%% %%
&Basic&(\@&&&(\?&&& Q@&&&
ףp=
@&'Diluted'HzG@'''{Gz?''' Q@'''
Gz@'(%Weightedaverage ordinary shares used~
(((~
(2((~
( ((~
(
())!in per share calculations  basic*%Weightedaverage ordinary shares used~
***~
***~
* **~
*
¾*++#in per share calculations  diluted,$____________________________1.)Created by Morningstar Document Research.0/(http://documentresearch.morningstar.com/$,zxM=PF0*8X>
@c//..******
**
((((((
((
''''''
''
&&&&&&
&&
######
##
""""""
""
!!!!!!
!!
l
dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??1!JAZZ PHARMACEUTICALS PUBLIC LIM Waterloo Road Dublin 4 Ireland
SIGNATURES!CONDENSED CONSOLIDATED BALANCE !CONDENSED CONSOLIDATED STATEMEN!CONDENSED CONSOLIDATED STAT (2)!Adoption of New Accounting Stan!3 Cash and AvailableforSale Sec!3 Cash and AvailableforSale (1)4 Fair Value Measurement!5 Derivative Instruments and He!5 Derivative Instruments an (1)!5 Derivative Instruments an (2)!5 Derivative Instruments an (3)!5 Derivative Instruments an (4)
6 Inventories!7 Goodwill and Intangible Asset!7 Goodwill and Intangible A (1)!7 Goodwill and Intangible A (2)8 Certain Balance Sheet Items8 Certain Balance Sheet I (1)9 Debt
Maturities11 Shareholders Equity11 Shareholders Equity (1)!Accumulated Other Comprehensive!12 Net Income per Ordinary Shar!12 Net Income per Ordinary (1)
13 Revenues13 Revenues (1)13 Revenues (2)!Contract Liabilities Deferred R14 ShareBased Compensation
Share OptionsRestricted Stock Units!Continued Emphasis on Research Continued Emphasis on Rese (1)Results of Operations
Revenues!Research and Development Expens!To continue to grow our businesContractual Obligations!Issuer Purchases of Equity Secu!Issuer Purchases of Equity (1)Base Rent Schedule!CompanyPlanGrant NoticeAgreemen!Additional TermsAcknowledgement!CompanyPlanRSUsAwardGrant Notic!Additional TermsAcknowledge (1)U }6}$
Jazz Pharmaceuticals plc10Q
11/06/2018A9CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME
Three Months Ended
Nine Months Ended
September 30,
September 30,~
~
~
~
Net income~
~
~
2
~
f
*"Other comprehensive income (loss):
0(Foreign currency translation adjustments~
D~
~
^Q~
5Unrealized gain (loss) on hedging activities,~
~
"~
R~
2*net of tax expense (benefit) of $107, $56,%$758 and ($137), respectively)!Other comprehensive income (loss)~
jP~
~
>~
* "Total comprehensive income~
zm~
~
n2~
D$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/8 eYMA5u"pLh=PF0*8X>
@
l K?8
dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??1!JAZZ PHARMACEUTICALS PUBLIC LIM Waterloo Road Dublin 4 Ireland
SIGNATURES!CONDENSED CONSOLIDATED BALANCE !CONDENSED CONSOLIDATED STATEMEN!CONDENSED CONSOLIDATED STAT (1)!Adoption of New Accounting Stan!3 Cash and AvailableforSale Sec!3 Cash and AvailableforSale (1)4 Fair Value Measurement!5 Derivative Instruments and He!5 Derivative Instruments an (1)!5 Derivative Instruments an (2)!5 Derivative Instruments an (3)!5 Derivative Instruments an (4)
6 Inventories!7 Goodwill and Intangible Asset!7 Goodwill and Intangible A (1)!7 Goodwill and Intangible A (2)8 Certain Balance Sheet Items8 Certain Balance Sheet I (1)9 Debt
Maturities11 Shareholders Equity11 Shareholders Equity (1)!Accumulated Other Comprehensive!12 Net Income per Ordinary Shar!12 Net Income per Ordinary (1)
13 Revenues13 Revenues (1)13 Revenues (2)!Contract Liabilities Deferred R14 ShareBased Compensation
Share OptionsRestricted Stock Units!Continued Emphasis on Research Continued Emphasis on Rese (1)Results of Operations
Revenues!Research and Development Expens!To continue to grow our businesContractual Obligations!Issuer Purchases of Equity Secu!Issuer Purchases of Equity (1)Base Rent Schedule!CompanyPlanGrant NoticeAgreemen!Additional TermsAcknowledgement!CompanyPlanRSUsAwardGrant Notic!Additional TermsAcknowledge (1)U }U5}$
K
Jazz Pharmaceuticals plc10Q
11/06/20187/CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
Nine Months Ended
September 30,~
~
Operating activities
Net income~
2~
f.&Adjustments to reconcile net income to2*net cash provided by operating activities:%Intangible asset amortization~
.u ~
r
Sharebased compensation~
~
nImpairment charges~
B Depreciation~
~
"4,Acquired inprocess research and development ~
""Loss on disposal of assets~
2
~
Deferred income taxes~
:F~
F3+Provision for losses on accounts receivable~
I~
and inventory/'Loss on extinguishment and modification~
F of debt2*Amortization of debt discount and deferred~
v~
,financing costs#Other noncash transactions~
l~
B*"Changes in assets and liabilities:Dh
locWK?]m7j
>wub !"#$%&'()*+,./0123456789:;<=>? Accounts receivable~
~
!Inventories~
!!!~
!!1")Prepaid expenses and other current assets~
"6m""~
"Z"#Other longterm assets~
###~
#~#$Accounts payable~
$$$~
$_$%Accrued liabilities~
%%%~
%%&Income taxes payable~
&F%&&~
&&'Deferred revenue~
'&''~
'i'%(Other noncurrent liabilities~
(2q((~
((1))Net cash provided by operating activities~
)z#))~
)B)*Investing activities***+%Proceeds from maturity of investments~
+""++~
+' +(, Net proceeds from sale of assets~
,r,, ,,4,Acquired inprocess research and development ~
L2.*Purchases of property, plant and equipment~
....~
.b.(/ Acquisition of intangible assets~
/8// //"0Acquisition of investments~
0"'00~
0L01%Net cash used in investing activities~
111~
112Financing activities222/3'Proceeds from employee equity incentive~
3b!33~
3&d34and purchase plans25*Proceeds from tenant improvement allowance~
555 556on buildtosuit lease*7"Net proceeds from issuance of debt 777~
7%"728*Repayments under revolving credit facility 888~
88*9"Payment of debt modification costs~
999 99:%Payment of employee withholding taxes~
:b::~
:.:%;related to sharebased awards$<Repayments of longterm debt~
<<<~
<
Y<=Share repurchases~
=L==~
=^=>%Net cash used in financing activities~
>z>>~
>fx>1?)Effect of exchange rates on cash and cash~
???~
?C?DlJsXi@cz@ABCDEFGHIJ@equivalents0A(Net increase (decrease) in cash and cash~
A^AA~
AABequivalents/C'Cash and cash equivalents, at beginning~
CΏCC~
C.VCD of period3E+Cash and cash equivalents, at end of period~
E*uEE~
EkEFG$H____________________________1I)Created by Morningstar Document Research.0J(http://documentresearch.morningstar.com/&u^_SG=PF0*8X>
@[JJIIHHEEEECCCCAAAA????>>>>====<<<<::::9999888877775555333311110000////....,,,,++++))))((((''''&&&&%%%%$$$$####""""!!!!
l c
dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??1!JAZZ PHARMACEUTICALS PUBLIC LIM Waterloo Road Dublin 4 Ireland
SIGNATURES!CONDENSED CONSOLIDATED BALANCE !CONDENSED CONSOLIDATED STATEMEN!CONDENSED CONSOLIDATED STAT (1)!CONDENSED CONSOLIDATED STAT (2)!3 Cash and AvailableforSale Sec!3 Cash and AvailableforSale (1)4 Fair Value Measurement!5 Derivative Instruments and He!5 Derivative Instruments an (1)!5 Derivative Instruments an (2)!5 Derivative Instruments an (3)!5 Derivative Instruments an (4)
6 Inventories!7 Goodwill and Intangible Asset!7 Goodwill and Intangible A (1)!7 Goodwill and Intangible A (2)8 Certain Balance Sheet Items8 Certain Balance Sheet I (1)9 Debt
Maturities11 Shareholders Equity11 Shareholders Equity (1)!Accumulated Other Comprehensive!12 Net Income per Ordinary Shar!12 Net Income per Ordinary (1)
13 Revenues13 Revenues (1)13 Revenues (2)!Contract Liabilities Deferred R14 ShareBased Compensation
Share OptionsRestricted Stock Units!Continued Emphasis on Research Continued Emphasis on Rese (1)Results of Operations
Revenues!Research and Development Expens!To continue to grow our businesContractual Obligations!Issuer Purchases of Equity Secu!Issuer Purchases of Equity (1)Base Rent Schedule!CompanyPlanGrant NoticeAgreemen!Additional TermsAcknowledgement!CompanyPlanRSUsAwardGrant Notic!Additional TermsAcknowledge (1)U }+}$
Jazz Pharmaceuticals plc10Q
11/06/2018,$Adoption of New Accounting Standards
$
Balance at December 31, 2017
Transition Adjustments
Balance at January 1,~
Assets:
Deferred tax assets, net~
~
N
~
J%
Liabilities: Deferred revenue~
~
~
*u%Deferred revenue, noncurrent~
~
~
N%Deferred tax liabilities, net~
g~
0~
Shareholders' Equity: ,$Accumulated other comprehensive loss~
f~
~
gRetained earnings~
8~
~
8$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/8C znbVJ+bsnbV.=PF0*8X>
@
l 4
dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??1!JAZZ PHARMACEUTICALS PUBLIC LIM Waterloo Road Dublin 4 Ireland
SIGNATURES!CONDENSED CONSOLIDATED BALANCE !CONDENSED CONSOLIDATED STATEMEN!CONDENSED CONSOLIDATED STAT (1)!CONDENSED CONSOLIDATED STAT (2)!Adoption of New Accounting Stan!3 Cash and AvailableforSale (1)4 Fair Value Measurement!5 Derivative Instruments and He!5 Derivative Instruments an (1)!5 Derivative Instruments an (2)!5 Derivative Instruments an (3)!5 Derivative Instruments an (4)
6 Inventories!7 Goodwill and Intangible Asset!7 Goodwill and Intangible A (1)!7 Goodwill and Intangible A (2)8 Certain Balance Sheet Items8 Certain Balance Sheet I (1)9 Debt
Maturities11 Shareholders Equity11 Shareholders Equity (1)!Accumulated Other Comprehensive!12 Net Income per Ordinary Shar!12 Net Income per Ordinary (1)
13 Revenues13 Revenues (1)13 Revenues (2)!Contract Liabilities Deferred R14 ShareBased Compensation
Share OptionsRestricted Stock Units!Continued Emphasis on Research Continued Emphasis on Rese (1)Results of Operations
Revenues!Research and Development Expens!To continue to grow our businesContractual Obligations!Issuer Purchases of Equity Secu!Issuer Purchases of Equity (1)Base Rent Schedule!CompanyPlanGrant NoticeAgreemen!Additional TermsAcknowledgement!CompanyPlanRSUsAwardGrant Notic!Additional TermsAcknowledge (1)U }a}$
Jazz Pharmaceuticals plc10Q
11/06/20181)3. Cash and AvailableforSale Securities
September 30, 2018 Amortized
Gross
Gross
EstimatedCash andInvestmentsCost
Unrealized
Unrealized
Fair ValueCash
Gains
Losses
EquivalentsCash~
^'
$
$~
^'~
^'
$
Time deposits~
$  ~
$~
~
""Money market funds~
.  ~
.~
. Totals~
J@
$
$~
J@~
*u~
""$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/2I
ui]QE%< , =PF0*8X>
@R*
l ?
dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??1!JAZZ PHARMACEUTICALS PUBLIC LIM Waterloo Road Dublin 4 Ireland
SIGNATURES!CONDENSED CONSOLIDATED BALANCE !CONDENSED CONSOLIDATED STATEMEN!CONDENSED CONSOLIDATED STAT (1)!CONDENSED CONSOLIDATED STAT (2)!Adoption of New Accounting Stan!3 Cash and AvailableforSale Sec4 Fair Value Measurement!5 Derivative Instruments and He!5 Derivative Instruments an (1)!5 Derivative Instruments an (2)!5 Derivative Instruments an (3)!5 Derivative Instruments an (4)
6 Inventories!7 Goodwill and Intangible Asset!7 Goodwill and Intangible A (1)!7 Goodwill and Intangible A (2)8 Certain Balance Sheet Items8 Certain Balance Sheet I (1)9 Debt
Maturities11 Shareholders Equity11 Shareholders Equity (1)!Accumulated Other Comprehensive!12 Net Income per Ordinary Shar!12 Net Income per Ordinary (1)
13 Revenues13 Revenues (1)13 Revenues (2)!Contract Liabilities Deferred R14 ShareBased Compensation
Share OptionsRestricted Stock Units!Continued Emphasis on Research Continued Emphasis on Rese (1)Results of Operations
Revenues!Research and Development Expens!To continue to grow our businesContractual Obligations!Issuer Purchases of Equity Secu!Issuer Purchases of Equity (1)Base Rent Schedule!CompanyPlanGrant NoticeAgreemen!Additional TermsAcknowledgement!CompanyPlanRSUsAwardGrant Notic!Additional TermsAcknowledge (1)U }a}$
Jazz Pharmaceuticals plc10Q
11/06/20181)3. Cash and AvailableforSale Securities
December 31, 2017 Amortized
Gross
Gross
Estimated
Cash and CashInvestmentsCost
Unrealized
Unrealized
Fair ValueEquivalents
Gains
LossesCash~
N
$
$~
N
~
N
$
Time deposits~
W  ~
W~
8~
b
Money market funds~
 ~
~
Totals~
.$
$
$~
.$~
Ώ~
b
$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/2
ui]QE%8(@Q^th\4=PF0*8X>
@J)
l "{
dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??1!JAZZ PHARMACEUTICALS PUBLIC LIM Waterloo Road Dublin 4 Ireland
SIGNATURES!CONDENSED CONSOLIDATED BALANCE !CONDENSED CONSOLIDATED STATEMEN!CONDENSED CONSOLIDATED STAT (1)!CONDENSED CONSOLIDATED STAT (2)!Adoption of New Accounting Stan!3 Cash and AvailableforSale Sec!3 Cash and AvailableforSale (1)!5 Derivative Instruments and He!5 Derivative Instruments an (1)!5 Derivative Instruments an (2)!5 Derivative Instruments an (3)!5 Derivative Instruments an (4)
6 Inventories!7 Goodwill and Intangible Asset!7 Goodwill and Intangible A (1)!7 Goodwill and Intangible A (2)8 Certain Balance Sheet Items8 Certain Balance Sheet I (1)9 Debt
Maturities11 Shareholders Equity11 Shareholders Equity (1)!Accumulated Other Comprehensive!12 Net Income per Ordinary Shar!12 Net Income per Ordinary (1)
13 Revenues13 Revenues (1)13 Revenues (2)!Contract Liabilities Deferred R14 ShareBased Compensation
Share OptionsRestricted Stock Units!Continued Emphasis on Research Continued Emphasis on Rese (1)Results of Operations
Revenues!Research and Development Expens!To continue to grow our businesContractual Obligations!Issuer Purchases of Equity Secu!Issuer Purchases of Equity (1)Base Rent Schedule!CompanyPlanGrant NoticeAgreemen!Additional TermsAcknowledgement!CompanyPlanRSUsAwardGrant Notic!Additional TermsAcknowledge (1)U }m)}$
"
Jazz Pharmaceuticals plc10Q
11/06/2018!4. Fair Value Measurement
September 30, 2018
December 31, 2017QuotedSignificant
Total
QuotedSignificant
Total Prices in
Other Estimated
Prices in
Other Estimated
Active
Observable
Fair Value
Active
Observable
Fair ValueMarkets forInputs
Markets forInputs Identical (Level 2)
Identical (Level 2)Assets
Assets (Level 1)
(Level 1)Assets:
&Availableforsale securities:
Time deposits
$~
$~
$
$~
W~
WMoney market funds~
. ~
.~
~
Interest rate contracts ~
Bz~
Bz
~
j!~
j!*"Foreign exchange forward contracts ~
~
~
~
Totals~
.~
$~
BH0~
~
fk~
fLiabilities:
Interest rate contracts
$
$
$
$~
"~
"*"Foreign exchange forward contracts ~
~
~
fN~
fNTotals
$~
~
$~
T~
T$____________________________DVlymaU5&h>iSXTj^ !1 )Created by Morningstar Document Research.0!(http://documentresearch.morningstar.com/=PF0*8X>
@S!!
l t
dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??1!JAZZ PHARMACEUTICALS PUBLIC LIM Waterloo Road Dublin 4 Ireland
SIGNATURES!CONDENSED CONSOLIDATED BALANCE !CONDENSED CONSOLIDATED STATEMEN!CONDENSED CONSOLIDATED STAT (1)!CONDENSED CONSOLIDATED STAT (2)!Adoption of New Accounting Stan!3 Cash and AvailableforSale Sec!3 Cash and AvailableforSale (1)4 Fair Value Measurement!5 Derivative Instruments an (1)!5 Derivative Instruments an (2)!5 Derivative Instruments an (3)!5 Derivative Instruments an (4)
6 Inventories!7 Goodwill and Intangible Asset!7 Goodwill and Intangible A (1)!7 Goodwill and Intangible A (2)8 Certain Balance Sheet Items8 Certain Balance Sheet I (1)9 Debt
Maturities11 Shareholders Equity11 Shareholders Equity (1)!Accumulated Other Comprehensive!12 Net Income per Ordinary Shar!12 Net Income per Ordinary (1)
13 Revenues13 Revenues (1)13 Revenues (2)!Contract Liabilities Deferred R14 ShareBased Compensation
Share OptionsRestricted Stock Units!Continued Emphasis on Research Continued Emphasis on Rese (1)Results of Operations
Revenues!Research and Development Expens!To continue to grow our businesContractual Obligations!Issuer Purchases of Equity Secu!Issuer Purchases of Equity (1)Base Rent Schedule!CompanyPlanGrant NoticeAgreemen!Additional TermsAcknowledgement!CompanyPlanRSUsAwardGrant Notic!Additional TermsAcknowledge (1)U }6}$
Jazz Pharmaceuticals plc10Q
11/06/2018805. Derivative Instruments and Hedging Activities
Three Months Ended
Nine Months Ended
September 30,
September 30, Interest Rate Contracts:~
~
~
~

%Gain (loss) recognized in accumulated~
~
~
R
~
,$other comprehensive loss, net of tax1)Loss (gain) reclassified from accumulated~
~
~
N~
5other comprehensive loss to interest expense,
net of tax$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/.nbVJ>~+atzd<=PF0*8X>
@
l .
dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??1!JAZZ PHARMACEUTICALS PUBLIC LIM Waterloo Road Dublin 4 Ireland
SIGNATURES!CONDENSED CONSOLIDATED BALANCE !CONDENSED CONSOLIDATED STATEMEN!CONDENSED CONSOLIDATED STAT (1)!CONDENSED CONSOLIDATED STAT (2)!Adoption of New Accounting Stan!3 Cash and AvailableforSale Sec!3 Cash and AvailableforSale (1)4 Fair Value Measurement!5 Derivative Instruments and He!5 Derivative Instruments an (2)!5 Derivative Instruments an (3)!5 Derivative Instruments an (4)
6 Inventories!7 Goodwill and Intangible Asset!7 Goodwill and Intangible A (1)!7 Goodwill and Intangible A (2)8 Certain Balance Sheet Items8 Certain Balance Sheet I (1)9 Debt
Maturities11 Shareholders Equity11 Shareholders Equity (1)!Accumulated Other Comprehensive!12 Net Income per Ordinary Shar!12 Net Income per Ordinary (1)
13 Revenues13 Revenues (1)13 Revenues (2)!Contract Liabilities Deferred R14 ShareBased Compensation
Share OptionsRestricted Stock Units!Continued Emphasis on Research Continued Emphasis on Rese (1)Results of Operations
Revenues!Research and Development Expens!To continue to grow our businesContractual Obligations!Issuer Purchases of Equity Secu!Issuer Purchases of Equity (1)Base Rent Schedule!CompanyPlanGrant NoticeAgreemen!Additional TermsAcknowledgement!CompanyPlanRSUsAwardGrant Notic!Additional TermsAcknowledge (1)U }7}}$ }$}$
Jazz Pharmaceuticals plc10Q
11/06/2018805. Derivative Instruments and Hedging Activities
September 30, 2018Asset DerivativesLiability DerivativesBalance Sheet Location
Fair ValueBalance Sheet Location
Fair Value6
.Derivatives designated as hedging instruments:
Interest rate contractsOther current assets~
!Accrued liabilities
$ Other noncurrent assets~
X %Derivatives not designated as hedging instruments:*"Foreign exchange forward contractsOther current assets~
Accrued liabilities~
2*Total fair value of derivative instruments~
V~~
$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/6nbVJ>.F;#^x=PF0*8X>
@z
l ?
dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??1!JAZZ PHARMACEUTICALS PUBLIC LIM Waterloo Road Dublin 4 Ireland
SIGNATURES!CONDENSED CONSOLIDATED BALANCE !CONDENSED CONSOLIDATED STATEMEN!CONDENSED CONSOLIDATED STAT (1)!CONDENSED CONSOLIDATED STAT (2)!Adoption of New Accounting Stan!3 Cash and AvailableforSale Sec!3 Cash and AvailableforSale (1)4 Fair Value Measurement!5 Derivative Instruments and He!5 Derivative Instruments an (1)!5 Derivative Instruments an (3)!5 Derivative Instruments an (4)
6 Inventories!7 Goodwill and Intangible Asset!7 Goodwill and Intangible A (1)!7 Goodwill and Intangible A (2)8 Certain Balance Sheet Items8 Certain Balance Sheet I (1)9 Debt
Maturities11 Shareholders Equity11 Shareholders Equity (1)!Accumulated Other Comprehensive!12 Net Income per Ordinary Shar!12 Net Income per Ordinary (1)
13 Revenues13 Revenues (1)13 Revenues (2)!Contract Liabilities Deferred R14 ShareBased Compensation
Share OptionsRestricted Stock Units!Continued Emphasis on Research Continued Emphasis on Rese (1)Results of Operations
Revenues!Research and Development Expens!To continue to grow our businesContractual Obligations!Issuer Purchases of Equity Secu!Issuer Purchases of Equity (1)Base Rent Schedule!CompanyPlanGrant NoticeAgreemen!Additional TermsAcknowledgement!CompanyPlanRSUsAwardGrant Notic!Additional TermsAcknowledge (1)U }7}}$ }$}$
Jazz Pharmaceuticals plc10Q
11/06/2018805. Derivative Instruments and Hedging Activities
December 31, 2017Asset DerivativesLiability DerivativesBalance Sheet Location
Fair ValueBalance Sheet Location
Fair Value6
.Derivatives designated as hedging instruments:
Interest rate contracts Other noncurrent assets~
j!Accrued liabilities~
"%Derivatives not designated as hedging instruments:*"Foreign exchange forward contractsOther current assets~
Accrued liabilities~
fN2*Total fair value of derivative instruments~
~
T$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/4NnbVJ>/C;/#=PF0*8X>
@r
l P
dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??1!JAZZ PHARMACEUTICALS PUBLIC LIM Waterloo Road Dublin 4 Ireland
SIGNATURES!CONDENSED CONSOLIDATED BALANCE !CONDENSED CONSOLIDATED STATEMEN!CONDENSED CONSOLIDATED STAT (1)!CONDENSED CONSOLIDATED STAT (2)!Adoption of New Accounting Stan!3 Cash and AvailableforSale Sec!3 Cash and AvailableforSale (1)4 Fair Value Measurement!5 Derivative Instruments and He!5 Derivative Instruments an (1)!5 Derivative Instruments an (2)!5 Derivative Instruments an (4)
6 Inventories!7 Goodwill and Intangible Asset!7 Goodwill and Intangible A (1)!7 Goodwill and Intangible A (2)8 Certain Balance Sheet Items8 Certain Balance Sheet I (1)9 Debt
Maturities11 Shareholders Equity11 Shareholders Equity (1)!Accumulated Other Comprehensive!12 Net Income per Ordinary Shar!12 Net Income per Ordinary (1)
13 Revenues13 Revenues (1)13 Revenues (2)!Contract Liabilities Deferred R14 ShareBased Compensation
Share OptionsRestricted Stock Units!Continued Emphasis on Research Continued Emphasis on Rese (1)Results of Operations
Revenues!Research and Development Expens!To continue to grow our businesContractual Obligations!Issuer Purchases of Equity Secu!Issuer Purchases of Equity (1)Base Rent Schedule!CompanyPlanGrant NoticeAgreemen!Additional TermsAcknowledgement!CompanyPlanRSUsAwardGrant Notic!Additional TermsAcknowledge (1)U }$}$
Jazz Pharmaceuticals plc10Q
11/06/2018805. Derivative Instruments and Hedging Activities
September 30, 20187/Gross Amounts of Recognized Assets/ Liabilities0(Gross Amounts Offset in the Consolidated4 ,Net Amounts of Assets/ Liabilities Presented4
,Gross Amounts Not Offset in the Consolidated
Balance Sheet) !in the Consolidated Balance Sheet
Balance Sheet
Description
(
Derivative Financial Instruments
*
"Cash Collateral Received (Pledged)
Net AmountDerivative assets~
$~
~
$~
rDerivative liabilities~
~
~
&  $____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/.6 nbVJ>2=PF0*8X>
@
l b
dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??1!JAZZ PHARMACEUTICALS PUBLIC LIM Waterloo Road Dublin 4 Ireland
SIGNATURES!CONDENSED CONSOLIDATED BALANCE !CONDENSED CONSOLIDATED STATEMEN!CONDENSED CONSOLIDATED STAT (1)!CONDENSED CONSOLIDATED STAT (2)!Adoption of New Accounting Stan!3 Cash and AvailableforSale Sec!3 Cash and AvailableforSale (1)4 Fair Value Measurement!5 Derivative Instruments and He!5 Derivative Instruments an (1)!5 Derivative Instruments an (2)!5 Derivative Instruments an (3)
6 Inventories!7 Goodwill and Intangible Asset!7 Goodwill and Intangible A (1)!7 Goodwill and Intangible A (2)8 Certain Balance Sheet Items8 Certain Balance Sheet I (1)9 Debt
Maturities11 Shareholders Equity11 Shareholders Equity (1)!Accumulated Other Comprehensive!12 Net Income per Ordinary Shar!12 Net Income per Ordinary (1)
13 Revenues13 Revenues (1)13 Revenues (2)!Contract Liabilities Deferred R14 ShareBased Compensation
Share OptionsRestricted Stock Units!Continued Emphasis on Research Continued Emphasis on Rese (1)Results of Operations
Revenues!Research and Development Expens!To continue to grow our businesContractual Obligations!Issuer Purchases of Equity Secu!Issuer Purchases of Equity (1)Base Rent Schedule!CompanyPlanGrant NoticeAgreemen!Additional TermsAcknowledgement!CompanyPlanRSUsAwardGrant Notic!Additional TermsAcknowledge (1)U }$}$
Jazz Pharmaceuticals plc10Q
11/06/2018805. Derivative Instruments and Hedging Activities
December 31, 20177/Gross Amounts of Recognized Assets/ Liabilities0(Gross Amounts Offset in the Consolidated4 ,Net Amounts of Assets/ Liabilities Presented4
,Gross Amounts Not Offset in the Consolidated
Balance Sheet) !in the Consolidated Balance Sheet
Balance Sheet
Description
(
Derivative Financial Instruments
*
"Cash Collateral Received (Pledged)
Net AmountDerivative assets~
$~
~
V
$~
Derivative liabilities~
V ~
V~
 $____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/.5 nbVJ>3=PF0*8X>
@
l up
dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??1!JAZZ PHARMACEUTICALS PUBLIC LIM Waterloo Road Dublin 4 Ireland
SIGNATURES!CONDENSED CONSOLIDATED BALANCE !CONDENSED CONSOLIDATED STATEMEN!CONDENSED CONSOLIDATED STAT (1)!CONDENSED CONSOLIDATED STAT (2)!Adoption of New Accounting Stan!3 Cash and AvailableforSale Sec!3 Cash and AvailableforSale (1)4 Fair Value Measurement!5 Derivative Instruments and He!5 Derivative Instruments an (1)!5 Derivative Instruments an (2)!5 Derivative Instruments an (3)!5 Derivative Instruments an (4)!7 Goodwill and Intangible Asset!7 Goodwill and Intangible A (1)!7 Goodwill and Intangible A (2)8 Certain Balance Sheet Items8 Certain Balance Sheet I (1)9 Debt
Maturities11 Shareholders Equity11 Shareholders Equity (1)!Accumulated Other Comprehensive!12 Net Income per Ordinary Shar!12 Net Income per Ordinary (1)
13 Revenues13 Revenues (1)13 Revenues (2)!Contract Liabilities Deferred R14 ShareBased Compensation
Share OptionsRestricted Stock Units!Continued Emphasis on Research Continued Emphasis on Rese (1)Results of Operations
Revenues!Research and Development Expens!To continue to grow our businesContractual Obligations!Issuer Purchases of Equity Secu!Issuer Purchases of Equity (1)Base Rent Schedule!CompanyPlanGrant NoticeAgreemen!Additional TermsAcknowledgement!CompanyPlanRSUsAwardGrant Notic!Additional TermsAcknowledge (1)U }0}$
Jazz Pharmaceuticals plc10Q
11/06/20186. Inventories
September 30,
December 31,~
~
Raw materials~
&~
Z7
Work in process~
"~
~
2
Finished goods~
~
.wTotal inventories~
~
$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/.5xl`*u=PF0*8X>
@z
l R
dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??1!JAZZ PHARMACEUTICALS PUBLIC LIM Waterloo Road Dublin 4 Ireland
SIGNATURES!CONDENSED CONSOLIDATED BALANCE !CONDENSED CONSOLIDATED STATEMEN!CONDENSED CONSOLIDATED STAT (1)!CONDENSED CONSOLIDATED STAT (2)!Adoption of New Accounting Stan!3 Cash and AvailableforSale Sec!3 Cash and AvailableforSale (1)4 Fair Value Measurement!5 Derivative Instruments and He!5 Derivative Instruments an (1)!5 Derivative Instruments an (2)!5 Derivative Instruments an (3)!5 Derivative Instruments an (4)
6 Inventories!7 Goodwill and Intangible A (1)!7 Goodwill and Intangible A (2)8 Certain Balance Sheet Items8 Certain Balance Sheet I (1)9 Debt
Maturities11 Shareholders Equity11 Shareholders Equity (1)!Accumulated Other Comprehensive!12 Net Income per Ordinary Shar!12 Net Income per Ordinary (1)
13 Revenues13 Revenues (1)13 Revenues (2)!Contract Liabilities Deferred R14 ShareBased Compensation
Share OptionsRestricted Stock Units!Continued Emphasis on Research Continued Emphasis on Rese (1)Results of Operations
Revenues!Research and Development Expens!To continue to grow our businesContractual Obligations!Issuer Purchases of Equity Secu!Issuer Purchases of Equity (1)Base Rent Schedule!CompanyPlanGrant NoticeAgreemen!Additional TermsAcknowledgement!CompanyPlanRSUsAwardGrant Notic!Additional TermsAcknowledge (1)U }y#}$
Jazz Pharmaceuticals plc10Q
11/06/2018)!7. Goodwill and Intangible Assets $
Balance at December 31, 2017~
F9
Foreign exchange~
%Balance at September 30, 2018~
8
$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/(T}qeYMbVJ"=PF0*8X>
@2
l ד
dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??1!JAZZ PHARMACEUTICALS PUBLIC LIM Waterloo Road Dublin 4 Ireland
SIGNATURES!CONDENSED CONSOLIDATED BALANCE !CONDENSED CONSOLIDATED STATEMEN!CONDENSED CONSOLIDATED STAT (1)!CONDENSED CONSOLIDATED STAT (2)!Adoption of New Accounting Stan!3 Cash and AvailableforSale Sec!3 Cash and AvailableforSale (1)4 Fair Value Measurement!5 Derivative Instruments and He!5 Derivative Instruments an (1)!5 Derivative Instruments an (2)!5 Derivative Instruments an (3)!5 Derivative Instruments an (4)
6 Inventories!7 Goodwill and Intangible Asset!7 Goodwill and Intangible A (2)8 Certain Balance Sheet Items8 Certain Balance Sheet I (1)9 Debt
Maturities11 Shareholders Equity11 Shareholders Equity (1)!Accumulated Other Comprehensive!12 Net Income per Ordinary Shar!12 Net Income per Ordinary (1)
13 Revenues13 Revenues (1)13 Revenues (2)!Contract Liabilities Deferred R14 ShareBased Compensation
Share OptionsRestricted Stock Units!Continued Emphasis on Research Continued Emphasis on Rese (1)Results of Operations
Revenues!Research and Development Expens!To continue to grow our businesContractual Obligations!Issuer Purchases of Equity Secu!Issuer Purchases of Equity (1)Base Rent Schedule!CompanyPlanGrant NoticeAgreemen!Additional TermsAcknowledgement!CompanyPlanRSUsAwardGrant Notic!Additional TermsAcknowledge (1)U }+} }$
Jazz Pharmaceuticals plc10Q
11/06/2018)!7. Goodwill and Intangible Assets
September 30, 2018
December 31, 2017 Remaining
GrossAccumulatedNet Book
GrossAccumulatedNet Book WeightedCarryingAmortization
ValueCarryingAmortization
Value
Average Useful
Amount
AmountLife
(In years)'Acquired developed technologies333333@~
~
*
~
~
~
^~
^Priority review voucher~

~
  Manufacturing contracts ~
~
f>
~
b~
:~
Trademarks ~
N~
~
z~
,$Total finitelived intangible assets~
P~
B
~
\~
~
~~
VìAcquired IPR&D assets~
B 
~
B~
~
Total intangible assets~
~
B
~
F~
b~
~~
Ե$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/<}qeYM 0fWD8,=PF0*8X>
@B
l آ
dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??1!JAZZ PHARMACEUTICALS PUBLIC LIM Waterloo Road Dublin 4 Ireland
SIGNATURES!CONDENSED CONSOLIDATED BALANCE !CONDENSED CONSOLIDATED STATEMEN!CONDENSED CONSOLIDATED STAT (1)!CONDENSED CONSOLIDATED STAT (2)!Adoption of New Accounting Stan!3 Cash and AvailableforSale Sec!3 Cash and AvailableforSale (1)4 Fair Value Measurement!5 Derivative Instruments and He!5 Derivative Instruments an (1)!5 Derivative Instruments an (2)!5 Derivative Instruments an (3)!5 Derivative Instruments an (4)
6 Inventories!7 Goodwill and Intangible Asset!7 Goodwill and Intangible A (1)8 Certain Balance Sheet Items8 Certain Balance Sheet I (1)9 Debt
Maturities11 Shareholders Equity11 Shareholders Equity (1)!Accumulated Other Comprehensive!12 Net Income per Ordinary Shar!12 Net Income per Ordinary (1)
13 Revenues13 Revenues (1)13 Revenues (2)!Contract Liabilities Deferred R14 ShareBased Compensation
Share OptionsRestricted Stock Units!Continued Emphasis on Research Continued Emphasis on Rese (1)Results of Operations
Revenues!Research and Development Expens!To continue to grow our businesContractual Obligations!Issuer Purchases of Equity Secu!Issuer Purchases of Equity (1)Base Rent Schedule!CompanyPlanGrant NoticeAgreemen!Additional TermsAcknowledgement!CompanyPlanRSUsAwardGrant Notic!Additional TermsAcknowledge (1)U }}$
Jazz Pharmaceuticals plc10Q
11/06/2018)!7. Goodwill and Intangible Assets
Year Ending December 31,
EstimatedAmortizationExpense
2018 (remainder)~
J
~
~
"m~
~
Y~
~
I~
~
>
Thereafter~
&ij
Total~
$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/6}qeYMkCpdX0=PF0*8X>
@j
l
dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??1!JAZZ PHARMACEUTICALS PUBLIC LIM Waterloo Road Dublin 4 Ireland
SIGNATURES!CONDENSED CONSOLIDATED BALANCE !CONDENSED CONSOLIDATED STATEMEN!CONDENSED CONSOLIDATED STAT (1)!CONDENSED CONSOLIDATED STAT (2)!Adoption of New Accounting Stan!3 Cash and AvailableforSale Sec!3 Cash and AvailableforSale (1)4 Fair Value Measurement!5 Derivative Instruments and He!5 Derivative Instruments an (1)!5 Derivative Instruments an (2)!5 Derivative Instruments an (3)!5 Derivative Instruments an (4)
6 Inventories!7 Goodwill and Intangible Asset!7 Goodwill and Intangible A (1)!7 Goodwill and Intangible A (2)8 Certain Balance Sheet I (1)9 Debt
Maturities11 Shareholders Equity11 Shareholders Equity (1)!Accumulated Other Comprehensive!12 Net Income per Ordinary Shar!12 Net Income per Ordinary (1)
13 Revenues13 Revenues (1)13 Revenues (2)!Contract Liabilities Deferred R14 ShareBased Compensation
Share OptionsRestricted Stock Units!Continued Emphasis on Research Continued Emphasis on Rese (1)Results of Operations
Revenues!Research and Development Expens!To continue to grow our businesContractual Obligations!Issuer Purchases of Equity Secu!Issuer Purchases of Equity (1)Base Rent Schedule!CompanyPlanGrant NoticeAgreemen!Additional TermsAcknowledgement!CompanyPlanRSUsAwardGrant Notic!Additional TermsAcknowledge (1)U }7}$
Jazz Pharmaceuticals plc10Q
11/06/2018&8. Certain Balance Sheet Items
September 30,
December 31,~
~
Buildtosuit facility~
/~
&(
Land and buildings~
~
~
&
Constructioninprogress~
~
SLeasehold improvements~
~
%Manufacturing equipment and machinery~
~
pComputer software~
*~
8Computer equipment~
~
:Furniture and fixtures~
}~
\Subtotal~
~
N6.Less accumulated depreciation and amortization~
)~
6*"Property, plant and equipment, net~
~
a
$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/<th\PsO_#=PF0*8X>
@
l
dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??1!JAZZ PHARMACEUTICALS PUBLIC LIM Waterloo Road Dublin 4 Ireland
SIGNATURES!CONDENSED CONSOLIDATED BALANCE !CONDENSED CONSOLIDATED STATEMEN!CONDENSED CONSOLIDATED STAT (1)!CONDENSED CONSOLIDATED STAT (2)!Adoption of New Accounting Stan!3 Cash and AvailableforSale Sec!3 Cash and AvailableforSale (1)4 Fair Value Measurement!5 Derivative Instruments and He!5 Derivative Instruments an (1)!5 Derivative Instruments an (2)!5 Derivative Instruments an (3)!5 Derivative Instruments an (4)
6 Inventories!7 Goodwill and Intangible Asset!7 Goodwill and Intangible A (1)!7 Goodwill and Intangible A (2)8 Certain Balance Sheet Items9 Debt
Maturities11 Shareholders Equity11 Shareholders Equity (1)!Accumulated Other Comprehensive!12 Net Income per Ordinary Shar!12 Net Income per Ordinary (1)
13 Revenues13 Revenues (1)13 Revenues (2)!Contract Liabilities Deferred R14 ShareBased Compensation
Share OptionsRestricted Stock Units!Continued Emphasis on Research Continued Emphasis on Rese (1)Results of Operations
Revenues!Research and Development Expens!To continue to grow our businesContractual Obligations!Issuer Purchases of Equity Secu!Issuer Purchases of Equity (1)Base Rent Schedule!CompanyPlanGrant NoticeAgreemen!Additional TermsAcknowledgement!CompanyPlanRSUsAwardGrant Notic!Additional TermsAcknowledge (1)U }m)}$
Jazz Pharmaceuticals plc10Q
11/06/2018&8. Certain Balance Sheet Items
September 30,
December 31,~
~
*"Rebates and other sales deductions~
e~
b"
Estimated loss contingency~
f

*"Employee compensation and benefits~
~
JZClinical trial accruals~
~
"&Selling and marketing accruals~
6[~
1"Inventoryrelated accruals~
j3~
. Royalties~
v3~
}Accrued interest~
)~
rSales returns reserve~
&~
9Professional fees~
%~
62)!Derivative instrument liabilities~
~
T
Other~
R~
Ɲ!Total accrued liabilities~
~
!$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/@ Dth\Ps2eN#maU=PF0*8X>
@
!
l
dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??1!JAZZ PHARMACEUTICALS PUBLIC LIM Waterloo Road Dublin 4 Ireland
SIGNATURES!CONDENSED CONSOLIDATED BALANCE !CONDENSED CONSOLIDATED STATEMEN!CONDENSED CONSOLIDATED STAT (1)!CONDENSED CONSOLIDATED STAT (2)!Adoption of New Accounting Stan!3 Cash and AvailableforSale Sec!3 Cash and AvailableforSale (1)4 Fair Value Measurement!5 Derivative Instruments and He!5 Derivative Instruments an (1)!5 Derivative Instruments an (2)!5 Derivative Instruments an (3)!5 Derivative Instruments an (4)
6 Inventories!7 Goodwill and Intangible Asset!7 Goodwill and Intangible A (1)!7 Goodwill and Intangible A (2)8 Certain Balance Sheet Items8 Certain Balance Sheet I (1)
Maturities11 Shareholders Equity11 Shareholders Equity (1)!Accumulated Other Comprehensive!12 Net Income per Ordinary Shar!12 Net Income per Ordinary (1)
13 Revenues13 Revenues (1)13 Revenues (2)!Contract Liabilities Deferred R14 ShareBased Compensation
Share OptionsRestricted Stock Units!Continued Emphasis on Research Continued Emphasis on Rese (1)Results of Operations
Revenues!Research and Development Expens!To continue to grow our businesContractual Obligations!Issuer Purchases of Equity Secu!Issuer Purchases of Equity (1)Base Rent Schedule!CompanyPlanGrant NoticeAgreemen!Additional TermsAcknowledgement!CompanyPlanRSUsAwardGrant Notic!Additional TermsAcknowledge (1)U }0.}$
Jazz Pharmaceuticals plc10Q
11/06/20189. Debt
September 30,
December 31,~
~
2021 Notes~
b#~
b#.
&Unamortized discount and debt issuance~
~
costs on 2021 Notes2021 Notes, net~
~
2024 Notes~
b#~
b#.&Unamortized discount and debt issuance~
5~
Pcosts on 2024 Notes2024 Notes, net~
N~
i Term loan~
'~
(
Total debt~
Ia~
`Less current portion~
~
vzTotal longterm debt~
@_~
F^$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/BXsg4HP1Q;/#=PF0*8X>
@
l 7
dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??1!JAZZ PHARMACEUTICALS PUBLIC LIM Waterloo Road Dublin 4 Ireland
SIGNATURES!CONDENSED CONSOLIDATED BALANCE !CONDENSED CONSOLIDATED STATEMEN!CONDENSED CONSOLIDATED STAT (1)!CONDENSED CONSOLIDATED STAT (2)!Adoption of New Accounting Stan!3 Cash and AvailableforSale Sec!3 Cash and AvailableforSale (1)4 Fair Value Measurement!5 Derivative Instruments and He!5 Derivative Instruments an (1)!5 Derivative Instruments an (2)!5 Derivative Instruments an (3)!5 Derivative Instruments an (4)
6 Inventories!7 Goodwill and Intangible Asset!7 Goodwill and Intangible A (1)!7 Goodwill and Intangible A (2)8 Certain Balance Sheet Items8 Certain Balance Sheet I (1)9 Debt11 Shareholders Equity11 Shareholders Equity (1)!Accumulated Other Comprehensive!12 Net Income per Ordinary Shar!12 Net Income per Ordinary (1)
13 Revenues13 Revenues (1)13 Revenues (2)!Contract Liabilities Deferred R14 ShareBased Compensation
Share OptionsRestricted Stock Units!Continued Emphasis on Research Continued Emphasis on Rese (1)Results of Operations
Revenues!Research and Development Expens!To continue to grow our businesContractual Obligations!Issuer Purchases of Equity Secu!Issuer Purchases of Equity (1)Base Rent Schedule!CompanyPlanGrant NoticeAgreemen!Additional TermsAcknowledgement!CompanyPlanRSUsAwardGrant Notic!Additional TermsAcknowledge (1)U }}$
Jazz Pharmaceuticals plc10Q
11/06/2018
Maturities
Year Ending December 31,+
#Scheduled LongTerm Debt Maturities2018 (remainder)~
j~
~
~
~
~
~
"%~
~
Thereafter~
:B
Total~
on$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/2pd4[3p=PF0*8X>
@Z
l
dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??1!JAZZ PHARMACEUTICALS PUBLIC LIM Waterloo Road Dublin 4 Ireland
SIGNATURES!CONDENSED CONSOLIDATED BALANCE !CONDENSED CONSOLIDATED STATEMEN!CONDENSED CONSOLIDATED STAT (1)!CONDENSED CONSOLIDATED STAT (2)!Adoption of New Accounting Stan!3 Cash and AvailableforSale Sec!3 Cash and AvailableforSale (1)4 Fair Value Measurement!5 Derivative Instruments and He!5 Derivative Instruments an (1)!5 Derivative Instruments an (2)!5 Derivative Instruments an (3)!5 Derivative Instruments an (4)
6 Inventories!7 Goodwill and Intangible Asset!7 Goodwill and Intangible A (1)!7 Goodwill and Intangible A (2)8 Certain Balance Sheet Items8 Certain Balance Sheet I (1)9 Debt
Maturities11 Shareholders Equity (1)!Accumulated Other Comprehensive!12 Net Income per Ordinary Shar!12 Net Income per Ordinary (1)
13 Revenues13 Revenues (1)13 Revenues (2)!Contract Liabilities Deferred R14 ShareBased Compensation
Share OptionsRestricted Stock Units!Continued Emphasis on Research Continued Emphasis on Rese (1)Results of Operations
Revenues!Research and Development Expens!To continue to grow our businesContractual Obligations!Issuer Purchases of Equity Secu!Issuer Purchases of Equity (1)Base Rent Schedule!CompanyPlanGrant NoticeAgreemen!Additional TermsAcknowledgement!CompanyPlanRSUsAwardGrant Notic!Additional TermsAcknowledge (1)U }7}$
Jazz Pharmaceuticals plc10Q
11/06/201811. Shareholders Equity
"
Total Shareholders' Equity/'Shareholders' equity at January 1, 2018~
&6.Effect of adoption of new accounting standards~
Z2
*Issuance of ordinary shares in conjunction~
b!
3+with employee equity incentive and purchase
plans%Employee withholding taxes related to~
bsharebased awards Sharebased compensation~
Shares repurchased~
L Other comprehensive loss~
>
Net income~
2%Shareholders' equity at September 30,~
Ÿ~
$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/<{ocW'TqSo$
=PF0*8X>
@j
l
dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??1!JAZZ PHARMACEUTICALS PUBLIC LIM Waterloo Road Dublin 4 Ireland
SIGNATURES!CONDENSED CONSOLIDATED BALANCE !CONDENSED CONSOLIDATED STATEMEN!CONDENSED CONSOLIDATED STAT (1)!CONDENSED CONSOLIDATED STAT (2)!Adoption of New Accounting Stan!3 Cash and AvailableforSale Sec!3 Cash and AvailableforSale (1)4 Fair Value Measurement!5 Derivative Instruments and He!5 Derivative Instruments an (1)!5 Derivative Instruments an (2)!5 Derivative Instruments an (3)!5 Derivative Instruments an (4)
6 Inventories!7 Goodwill and Intangible Asset!7 Goodwill and Intangible A (1)!7 Goodwill and Intangible A (2)8 Certain Balance Sheet Items8 Certain Balance Sheet I (1)9 Debt
Maturities11 Shareholders Equity!Accumulated Other Comprehensive!12 Net Income per Ordinary Shar!12 Net Income per Ordinary (1)
13 Revenues13 Revenues (1)13 Revenues (2)!Contract Liabilities Deferred R14 ShareBased Compensation
Share OptionsRestricted Stock Units!Continued Emphasis on Research Continued Emphasis on Rese (1)Results of Operations
Revenues!Research and Development Expens!To continue to grow our businesContractual Obligations!Issuer Purchases of Equity Secu!Issuer Purchases of Equity (1)Base Rent Schedule!CompanyPlanGrant NoticeAgreemen!Additional TermsAcknowledgement!CompanyPlanRSUsAwardGrant Notic!Additional TermsAcknowledge (1)U }$4}$
Jazz Pharmaceuticals plc10Q
11/06/201811. Shareholders Equity
"
Total Shareholders' Equity/'Shareholders' equity at January 1, 2017~
nrIssuance of 2024 Notes~
$ 2
*Issuance of ordinary shares in conjunction~
&d
3+with employee equity incentive and purchase
plans%Employee withholding taxes related to~
.sharebased awards Sharebased compensation~
Shares repurchased~
^"Other comprehensive income~
*
Net income~
f%Shareholders' equity at September 30,~
ƶ~
$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/<{ocW'lk:, =PF0*8X>
@j
l
dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??1!JAZZ PHARMACEUTICALS PUBLIC LIM Waterloo Road Dublin 4 Ireland
SIGNATURES!CONDENSED CONSOLIDATED BALANCE !CONDENSED CONSOLIDATED STATEMEN!CONDENSED CONSOLIDATED STAT (1)!CONDENSED CONSOLIDATED STAT (2)!Adoption of New Accounting Stan!3 Cash and AvailableforSale Sec!3 Cash and AvailableforSale (1)4 Fair Value Measurement!5 Derivative Instruments and He!5 Derivative Instruments an (1)!5 Derivative Instruments an (2)!5 Derivative Instruments an (3)!5 Derivative Instruments an (4)
6 Inventories!7 Goodwill and Intangible Asset!7 Goodwill and Intangible A (1)!7 Goodwill and Intangible A (2)8 Certain Balance Sheet Items8 Certain Balance Sheet I (1)9 Debt
Maturities11 Shareholders Equity11 Shareholders Equity (1)!12 Net Income per Ordinary Shar!12 Net Income per Ordinary (1)
13 Revenues13 Revenues (1)13 Revenues (2)!Contract Liabilities Deferred R14 ShareBased Compensation
Share OptionsRestricted Stock Units!Continued Emphasis on Research Continued Emphasis on Rese (1)Results of Operations
Revenues!Research and Development Expens!To continue to grow our businesContractual Obligations!Issuer Purchases of Equity Secu!Issuer Purchases of Equity (1)Base Rent Schedule!CompanyPlanGrant NoticeAgreemen!Additional TermsAcknowledgement!CompanyPlanRSUsAwardGrant Notic!Additional TermsAcknowledge (1)U }0}$
Jazz Pharmaceuticals plc10Q
11/06/2018,$Accumulated Other Comprehensive Loss
Net Unrealized
Foreign
Total$Gain From Hedging ActivitiesCurrency AccumulatedTranslation
Other
Adjustments
Comprehensive Loss$Balance at December 31, 2017~
*~
O~
f%Effect of adoption of ASU No. 201712~
~
"Balance at January 1, 2018~
~
O~
g0(Other comprehensive income (loss) before~
R~
^Q~
reclassifications%Amounts reclassified from accumulated~
N ~
N other comprehensive loss.&Other comprehensive income (loss), net~
R~
^Q~
>%Balance at September 30, 2018~
j~
~
$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/>
0znbVJXq}Y3\5)=PF0*8X>
@#
l *
dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??1!JAZZ PHARMACEUTICALS PUBLIC LIM Waterloo Road Dublin 4 Ireland
SIGNATURES!CONDENSED CONSOLIDATED BALANCE !CONDENSED CONSOLIDATED STATEMEN!CONDENSED CONSOLIDATED STAT (1)!CONDENSED CONSOLIDATED STAT (2)!Adoption of New Accounting Stan!3 Cash and AvailableforSale Sec!3 Cash and AvailableforSale (1)4 Fair Value Measurement!5 Derivative Instruments and He!5 Derivative Instruments an (1)!5 Derivative Instruments an (2)!5 Derivative Instruments an (3)!5 Derivative Instruments an (4)
6 Inventories!7 Goodwill and Intangible Asset!7 Goodwill and Intangible A (1)!7 Goodwill and Intangible A (2)8 Certain Balance Sheet Items8 Certain Balance Sheet I (1)9 Debt
Maturities11 Shareholders Equity11 Shareholders Equity (1)!Accumulated Other Comprehensive!12 Net Income per Ordinary (1)
13 Revenues13 Revenues (1)13 Revenues (2)!Contract Liabilities Deferred R14 ShareBased Compensation
Share OptionsRestricted Stock Units!Continued Emphasis on Research Continued Emphasis on Rese (1)Results of Operations
Revenues!Research and Development Expens!To continue to grow our businesContractual Obligations!Issuer Purchases of Equity Secu!Issuer Purchases of Equity (1)Base Rent Schedule!CompanyPlanGrant NoticeAgreemen!Additional TermsAcknowledgement!CompanyPlanRSUsAwardGrant Notic!Additional TermsAcknowledge (1)U }U5}$
Jazz Pharmaceuticals plc10Q
11/06/2018)!12. Net Income per Ordinary Share
Three Months Ended
Nine Months Ended
September 30,
September 30,~
~
~
~
Numerator:
Net income~
~
~
2~
fDenominator:
%Weightedaverage ordinary shares used~
~
2~
~
)!in per share calculations  basic4,Dilutive effect of employee equity incentive~
~
~
F~
and purchase plans%Weightedaverage ordinary shares used~
~
~
~
¾+#in per share calculations  diluted
&Net income per ordinary share:
Basic(\@(\? Q@
ףp=
@DilutedHzG@{Gz? Q@
Gz@$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/BX}qeYM:S&bDXz=PF0*8X>
@#
l :
dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??1!JAZZ PHARMACEUTICALS PUBLIC LIM Waterloo Road Dublin 4 Ireland
SIGNATURES!CONDENSED CONSOLIDATED BALANCE !CONDENSED CONSOLIDATED STATEMEN!CONDENSED CONSOLIDATED STAT (1)!CONDENSED CONSOLIDATED STAT (2)!Adoption of New Accounting Stan!3 Cash and AvailableforSale Sec!3 Cash and AvailableforSale (1)4 Fair Value Measurement!5 Derivative Instruments and He!5 Derivative Instruments an (1)!5 Derivative Instruments an (2)!5 Derivative Instruments an (3)!5 Derivative Instruments an (4)
6 Inventories!7 Goodwill and Intangible Asset!7 Goodwill and Intangible A (1)!7 Goodwill and Intangible A (2)8 Certain Balance Sheet Items8 Certain Balance Sheet I (1)9 Debt
Maturities11 Shareholders Equity11 Shareholders Equity (1)!Accumulated Other Comprehensive!12 Net Income per Ordinary Shar
13 Revenues13 Revenues (1)13 Revenues (2)!Contract Liabilities Deferred R14 ShareBased Compensation
Share OptionsRestricted Stock Units!Continued Emphasis on Research Continued Emphasis on Rese (1)Results of Operations
Revenues!Research and Development Expens!To continue to grow our businesContractual Obligations!Issuer Purchases of Equity Secu!Issuer Purchases of Equity (1)Base Rent Schedule!CompanyPlanGrant NoticeAgreemen!Additional TermsAcknowledgement!CompanyPlanRSUsAwardGrant Notic!Additional TermsAcknowledge (1)U }a/}
}$ }
}$ }
} $ }
}$
Jazz Pharmaceuticals plc10Q
11/06/2018)!12. Net Income per Ordinary Share
Three Months Ended
Nine Months Ended
September 30,
September 30,~
~
~
~
!
Exchangeable Senior Notes~
V
~
=
~
V
~
2
/'Options to purchase ordinary shares and~
"~
.~
>. ~
1RSUs"Ordinary shares under ESPP~
:~
B~
B ~
&$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/0}qeYMj H8znF=PF0*8X>
@Z
l M
dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??1!JAZZ PHARMACEUTICALS PUBLIC LIM Waterloo Road Dublin 4 Ireland
SIGNATURES!CONDENSED CONSOLIDATED BALANCE !CONDENSED CONSOLIDATED STATEMEN!CONDENSED CONSOLIDATED STAT (1)!CONDENSED CONSOLIDATED STAT (2)!Adoption of New Accounting Stan!3 Cash and AvailableforSale Sec!3 Cash and AvailableforSale (1)4 Fair Value Measurement!5 Derivative Instruments and He!5 Derivative Instruments an (1)!5 Derivative Instruments an (2)!5 Derivative Instruments an (3)!5 Derivative Instruments an (4)
6 Inventories!7 Goodwill and Intangible Asset!7 Goodwill and Intangible A (1)!7 Goodwill and Intangible A (2)8 Certain Balance Sheet Items8 Certain Balance Sheet I (1)9 Debt
Maturities11 Shareholders Equity11 Shareholders Equity (1)!Accumulated Other Comprehensive!12 Net Income per Ordinary Shar!12 Net Income per Ordinary (1)13 Revenues (1)13 Revenues (2)!Contract Liabilities Deferred R14 ShareBased Compensation
Share OptionsRestricted Stock Units!Continued Emphasis on Research Continued Emphasis on Rese (1)Results of Operations
Revenues!Research and Development Expens!To continue to grow our businesContractual Obligations!Issuer Purchases of Equity Secu!Issuer Purchases of Equity (1)Base Rent Schedule!CompanyPlanGrant NoticeAgreemen!Additional TermsAcknowledgement!CompanyPlanRSUsAwardGrant Notic!Additional TermsAcknowledge (1)U }%}$
Jazz Pharmaceuticals plc10Q
11/06/201813. Revenues
Three Months Ended
Nine Months Ended
September 30,
September 30,~
~
~
~
Xyrem~
~
~
R>
~
[5
Erwinaze/Erwinase~
~
V~
*/ ~
F! Defitelio/defibrotide~
F5~
~
~
Vyxeos~
H~
ޗ~
F~
ޗPrialt~
Z~
{~
E~
L
Other~
v;~
^~
6~
*Product sales, net~
d~
~
nU~
}G'Royalties and contract revenues~
BA~
<~
~
Total revenues~
~
>#~
UV~
Z)H$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/:
znbOWn'p=PF0*8X>
@z/
l x^
dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??1!JAZZ PHARMACEUTICALS PUBLIC LIM Waterloo Road Dublin 4 Ireland
SIGNATURES!CONDENSED CONSOLIDATED BALANCE !CONDENSED CONSOLIDATED STATEMEN!CONDENSED CONSOLIDATED STAT (1)!CONDENSED CONSOLIDATED STAT (2)!Adoption of New Accounting Stan!3 Cash and AvailableforSale Sec!3 Cash and AvailableforSale (1)4 Fair Value Measurement!5 Derivative Instruments and He!5 Derivative Instruments an (1)!5 Derivative Instruments an (2)!5 Derivative Instruments an (3)!5 Derivative Instruments an (4)
6 Inventories!7 Goodwill and Intangible Asset!7 Goodwill and Intangible A (1)!7 Goodwill and Intangible A (2)8 Certain Balance Sheet Items8 Certain Balance Sheet I (1)9 Debt
Maturities11 Shareholders Equity11 Shareholders Equity (1)!Accumulated Other Comprehensive!12 Net Income per Ordinary Shar!12 Net Income per Ordinary (1)
13 Revenues13 Revenues (2)!Contract Liabilities Deferred R14 ShareBased Compensation
Share OptionsRestricted Stock Units!Continued Emphasis on Research Continued Emphasis on Rese (1)Results of Operations
Revenues!Research and Development Expens!To continue to grow our businesContractual Obligations!Issuer Purchases of Equity Secu!Issuer Purchases of Equity (1)Base Rent Schedule!CompanyPlanGrant NoticeAgreemen!Additional TermsAcknowledgement!CompanyPlanRSUsAwardGrant Notic!Additional TermsAcknowledge (1)U }}$
Jazz Pharmaceuticals plc10Q
11/06/201813. Revenues
Three Months Ended
Nine Months Ended
September 30,
September 30,~
~
~
~
United States~
:
~
~
^N
~
:A
Europe~
~
f~
V~
o All other~
~
"~
V~
Total revenues~
~
>#~
UV~
Z)H$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/0NznbOZ=PF0*8X>
@
l sm
dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??1!JAZZ PHARMACEUTICALS PUBLIC LIM Waterloo Road Dublin 4 Ireland
SIGNATURES!CONDENSED CONSOLIDATED BALANCE !CONDENSED CONSOLIDATED STATEMEN!CONDENSED CONSOLIDATED STAT (1)!CONDENSED CONSOLIDATED STAT (2)!Adoption of New Accounting Stan!3 Cash and AvailableforSale Sec!3 Cash and AvailableforSale (1)4 Fair Value Measurement!5 Derivative Instruments and He!5 Derivative Instruments an (1)!5 Derivative Instruments an (2)!5 Derivative Instruments an (3)!5 Derivative Instruments an (4)
6 Inventories!7 Goodwill and Intangible Asset!7 Goodwill and Intangible A (1)!7 Goodwill and Intangible A (2)8 Certain Balance Sheet Items8 Certain Balance Sheet I (1)9 Debt
Maturities11 Shareholders Equity11 Shareholders Equity (1)!Accumulated Other Comprehensive!12 Net Income per Ordinary Shar!12 Net Income per Ordinary (1)
13 Revenues13 Revenues (1)!Contract Liabilities Deferred R14 ShareBased Compensation
Share OptionsRestricted Stock Units!Continued Emphasis on Research Continued Emphasis on Rese (1)Results of Operations
Revenues!Research and Development Expens!To continue to grow our businesContractual Obligations!Issuer Purchases of Equity Secu!Issuer Purchases of Equity (1)Base Rent Schedule!CompanyPlanGrant NoticeAgreemen!Additional TermsAcknowledgement!CompanyPlanRSUsAwardGrant Notic!Additional TermsAcknowledge (1)U }}$}$}$ }$}$}$ }$}$} $ }
$}$
Jazz Pharmaceuticals plc10Q
11/06/201813. Revenues
Three Months Ended
Nine Months Ended
September 30,
September 30,~
~
~
~
Express Scripts~
2
%
~
*
%
~
&
%
~
*
%McKesson~
> %~
: %~
J % ~
: %$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/,znb5"~rf>=PF0*8X>
@Z
l z
dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??1!JAZZ PHARMACEUTICALS PUBLIC LIM Waterloo Road Dublin 4 Ireland
SIGNATURES!CONDENSED CONSOLIDATED BALANCE !CONDENSED CONSOLIDATED STATEMEN!CONDENSED CONSOLIDATED STAT (1)!CONDENSED CONSOLIDATED STAT (2)!Adoption of New Accounting Stan!3 Cash and AvailableforSale Sec!3 Cash and AvailableforSale (1)4 Fair Value Measurement!5 Derivative Instruments and He!5 Derivative Instruments an (1)!5 Derivative Instruments an (2)!5 Derivative Instruments an (3)!5 Derivative Instruments an (4)
6 Inventories!7 Goodwill and Intangible Asset!7 Goodwill and Intangible A (1)!7 Goodwill and Intangible A (2)8 Certain Balance Sheet Items8 Certain Balance Sheet I (1)9 Debt
Maturities11 Shareholders Equity11 Shareholders Equity (1)!Accumulated Other Comprehensive!12 Net Income per Ordinary Shar!12 Net Income per Ordinary (1)
13 Revenues13 Revenues (1)13 Revenues (2)14 ShareBased Compensation
Share OptionsRestricted Stock Units!Continued Emphasis on Research Continued Emphasis on Rese (1)Results of Operations
Revenues!Research and Development Expens!To continue to grow our businesContractual Obligations!Issuer Purchases of Equity Secu!Issuer Purchases of Equity (1)Base Rent Schedule!CompanyPlanGrant NoticeAgreemen!Additional TermsAcknowledgement!CompanyPlanRSUsAwardGrant Notic!Additional TermsAcknowledge (1)U }0.}$
Jazz Pharmaceuticals plc10Q
11/06/2018/'Contract Liabilities  Deferred Revenue
Contract Liabilities'Balance as of December 31, 2017~
v)!Effect of adoption of ASU 201409~
.
&Amount recognized within royalties and~
"
contract revenues( Balance as of September 30, 2018~
$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/.wk_SG_p=PF0*8X>
@B
l ɋ
dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??1!JAZZ PHARMACEUTICALS PUBLIC LIM Waterloo Road Dublin 4 Ireland
SIGNATURES!CONDENSED CONSOLIDATED BALANCE !CONDENSED CONSOLIDATED STATEMEN!CONDENSED CONSOLIDATED STAT (1)!CONDENSED CONSOLIDATED STAT (2)!Adoption of New Accounting Stan!3 Cash and AvailableforSale Sec!3 Cash and AvailableforSale (1)4 Fair Value Measurement!5 Derivative Instruments and He!5 Derivative Instruments an (1)!5 Derivative Instruments an (2)!5 Derivative Instruments an (3)!5 Derivative Instruments an (4)
6 Inventories!7 Goodwill and Intangible Asset!7 Goodwill and Intangible A (1)!7 Goodwill and Intangible A (2)8 Certain Balance Sheet Items8 Certain Balance Sheet I (1)9 Debt
Maturities11 Shareholders Equity11 Shareholders Equity (1)!Accumulated Other Comprehensive!12 Net Income per Ordinary Shar!12 Net Income per Ordinary (1)
13 Revenues13 Revenues (1)13 Revenues (2)!Contract Liabilities Deferred R
Share OptionsRestricted Stock Units!Continued Emphasis on Research Continued Emphasis on Rese (1)Results of Operations
Revenues!Research and Development Expens!To continue to grow our businesContractual Obligations!Issuer Purchases of Equity Secu!Issuer Purchases of Equity (1)Base Rent Schedule!CompanyPlanGrant NoticeAgreemen!Additional TermsAcknowledgement!CompanyPlanRSUsAwardGrant Notic!Additional TermsAcknowledge (1)U }:}$
Jazz Pharmaceuticals plc10Q
11/06/2018$14. ShareBased Compensation
Three Months Ended
Nine Months Ended
September 30,
September 30,~
~
~
~
+
#Selling, general and administrative~
(
~
F
~
z
~
:
Research and development~
G~
H~
~
NCost of product sales~
~
~
zN~
C/'Total sharebased compensation expense,~
>~
ڧ~
~
npretax80Income tax benefit from sharebased compensation~
~
~
zC~
expense/'Total sharebased compensation expense,~
P~
D~
~
Ng
net of tax$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/8 vj^R?"u =PF0*8X>
@#
l [
dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??1!JAZZ PHARMACEUTICALS PUBLIC LIM Waterloo Road Dublin 4 Ireland
SIGNATURES!CONDENSED CONSOLIDATED BALANCE !CONDENSED CONSOLIDATED STATEMEN!CONDENSED CONSOLIDATED STAT (1)!CONDENSED CONSOLIDATED STAT (2)!Adoption of New Accounting Stan!3 Cash and AvailableforSale Sec!3 Cash and AvailableforSale (1)4 Fair Value Measurement!5 Derivative Instruments and He!5 Derivative Instruments an (1)!5 Derivative Instruments an (2)!5 Derivative Instruments an (3)!5 Derivative Instruments an (4)
6 Inventories!7 Goodwill and Intangible Asset!7 Goodwill and Intangible A (1)!7 Goodwill and Intangible A (2)8 Certain Balance Sheet Items8 Certain Balance Sheet I (1)9 Debt
Maturities11 Shareholders Equity11 Shareholders Equity (1)!Accumulated Other Comprehensive!12 Net Income per Ordinary Shar!12 Net Income per Ordinary (1)
13 Revenues13 Revenues (1)13 Revenues (2)!Contract Liabilities Deferred R14 ShareBased CompensationRestricted Stock Units!Continued Emphasis on Research Continued Emphasis on Rese (1)Results of Operations
Revenues!Research and Development Expens!To continue to grow our businesContractual Obligations!Issuer Purchases of Equity Secu!Issuer Purchases of Equity (1)Base Rent Schedule!CompanyPlanGrant NoticeAgreemen!Additional TermsAcknowledgement!CompanyPlanRSUsAwardGrant Notic!Additional TermsAcknowledge (1)U }6}$ }$}$ }$}
$ }$}$ }$
Jazz Pharmaceuticals plc10Q
11/06/2018
Share Options
Three Months Ended
Nine Months Ended
September 30,
September 30,~
~
~
~

%Shares underlying options granted (in~
~
^
~
~
thousands)Grant date fair valueףp=
J@(\F@ yG@
QXE@5BlackScholes option pricing model assumption
information:
Volatility~
%~
%~
%~
%Expected term (years)@333333@ @
333333@ Range of riskfree rates2.72.8%1.61.8% 2.22.8%
1.61.8%Expected dividend yield  %  %  %
 %$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/:8
ymaNg
@#
l T
dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??1!JAZZ PHARMACEUTICALS PUBLIC LIM Waterloo Road Dublin 4 Ireland
SIGNATURES!CONDENSED CONSOLIDATED BALANCE !CONDENSED CONSOLIDATED STATEMEN!CONDENSED CONSOLIDATED STAT (1)!CONDENSED CONSOLIDATED STAT (2)!Adoption of New Accounting Stan!3 Cash and AvailableforSale Sec!3 Cash and AvailableforSale (1)4 Fair Value Measurement!5 Derivative Instruments and He!5 Derivative Instruments an (1)!5 Derivative Instruments an (2)!5 Derivative Instruments an (3)!5 Derivative Instruments an (4)
6 Inventories!7 Goodwill and Intangible Asset!7 Goodwill and Intangible A (1)!7 Goodwill and Intangible A (2)8 Certain Balance Sheet Items8 Certain Balance Sheet I (1)9 Debt
Maturities11 Shareholders Equity11 Shareholders Equity (1)!Accumulated Other Comprehensive!12 Net Income per Ordinary Shar!12 Net Income per Ordinary (1)
13 Revenues13 Revenues (1)13 Revenues (2)!Contract Liabilities Deferred R14 ShareBased Compensation
Share Options!Continued Emphasis on Research Continued Emphasis on Rese (1)Results of Operations
Revenues!Research and Development Expens!To continue to grow our businesContractual Obligations!Issuer Purchases of Equity Secu!Issuer Purchases of Equity (1)Base Rent Schedule!CompanyPlanGrant NoticeAgreemen!Additional TermsAcknowledgement!CompanyPlanRSUsAwardGrant Notic!Additional TermsAcknowledge (1)U }!}$
Jazz Pharmaceuticals plc10Q
11/06/2018Restricted Stock Units
Three Months Ended
Nine Months Ended
September 30,
September 30,~
~
~
~
#
RSUs granted (in thousands)~
~
~
~
f
Grant date fair value(\e@33333b@ {G2b@
(\'a@$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/,pdXE#=PF0*8X>
@
l ̼
dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??1!JAZZ PHARMACEUTICALS PUBLIC LIM Waterloo Road Dublin 4 Ireland
SIGNATURES!CONDENSED CONSOLIDATED BALANCE !CONDENSED CONSOLIDATED STATEMEN!CONDENSED CONSOLIDATED STAT (1)!CONDENSED CONSOLIDATED STAT (2)!Adoption of New Accounting Stan!3 Cash and AvailableforSale Sec!3 Cash and AvailableforSale (1)4 Fair Value Measurement!5 Derivative Instruments and He!5 Derivative Instruments an (1)!5 Derivative Instruments an (2)!5 Derivative Instruments an (3)!5 Derivative Instruments an (4)
6 Inventories!7 Goodwill and Intangible Asset!7 Goodwill and Intangible A (1)!7 Goodwill and Intangible A (2)8 Certain Balance Sheet Items8 Certain Balance Sheet I (1)9 Debt
Maturities11 Shareholders Equity11 Shareholders Equity (1)!Accumulated Other Comprehensive!12 Net Income per Ordinary Shar!12 Net Income per Ordinary (1)
13 Revenues13 Revenues (1)13 Revenues (2)!Contract Liabilities Deferred R14 ShareBased Compensation
Share OptionsRestricted Stock Units Continued Emphasis on Rese (1)Results of Operations
Revenues!Research and Development Expens!To continue to grow our businesContractual Obligations!Issuer Purchases of Equity Secu!Issuer Purchases of Equity (1)Base Rent Schedule!CompanyPlanGrant NoticeAgreemen!Additional TermsAcknowledgement!CompanyPlanRSUsAwardGrant Notic!Additional TermsAcknowledge (1)U }$}a/}8
Jazz Pharmaceuticals plc10Q
11/06/20186.Continued Emphasis on Research and Development
Project
Disease Area
Status
SleepSolriamfetol (JZP110)/'EDS in obstructive sleep apnea, or OSA,7/NDA accepted for filing by FDA in first quarter
and EDS in narcolepsy3
+of 2018 with a target action date under the1)Prescription Drug User Fee Act, or PDUFA,1)of December 20, 2018; preparing to submit%a marketing authorization application0(to the European Medicines Agency in late~
$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/4pdXL@&u(maU=PF0*8X>
@
l *
dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??1!JAZZ PHARMACEUTICALS PUBLIC LIM Waterloo Road Dublin 4 Ireland
SIGNATURES!CONDENSED CONSOLIDATED BALANCE !CONDENSED CONSOLIDATED STATEMEN!CONDENSED CONSOLIDATED STAT (1)!CONDENSED CONSOLIDATED STAT (2)!Adoption of New Accounting Stan!3 Cash and AvailableforSale Sec!3 Cash and AvailableforSale (1)4 Fair Value Measurement!5 Derivative Instruments and He!5 Derivative Instruments an (1)!5 Derivative Instruments an (2)!5 Derivative Instruments an (3)!5 Derivative Instruments an (4)
6 Inventories!7 Goodwill and Intangible Asset!7 Goodwill and Intangible A (1)!7 Goodwill and Intangible A (2)8 Certain Balance Sheet Items8 Certain Balance Sheet I (1)9 Debt
Maturities11 Shareholders Equity11 Shareholders Equity (1)!Accumulated Other Comprehensive!12 Net Income per Ordinary Shar!12 Net Income per Ordinary (1)
13 Revenues13 Revenues (1)13 Revenues (2)!Contract Liabilities Deferred R14 ShareBased Compensation
Share OptionsRestricted Stock Units!Continued Emphasis on Research Results of Operations
Revenues!Research and Development Expens!To continue to grow our businesContractual Obligations!Issuer Purchases of Equity Secu!Issuer Purchases of Equity (1)Base Rent Schedule!CompanyPlanGrant NoticeAgreemen!Additional TermsAcknowledgement!CompanyPlanRSUsAwardGrant Notic!Additional TermsAcknowledge (1)U }a/}:}8
*
Jazz Pharmaceuticals plc10Q
11/06/20186.Continued Emphasis on Research and Development
Project
Disease Area
StatusSolriamfetol (JZP110)"EDS in Parkinson?s disease0(Enrollment in Phase 2 trial completed in5third quarter of 2018; topline data expected
early 2019/'JZP258 (oxybate; 90% sodium reduction)'EDS and cataplexy in narcolepsy0(Expect topline data in Phase 3 trial bysecond quarter of 2019JZP258Idiopathic hypersomnia%Expect to commence patient enrollment2*in Phase 3 trial in fourth quarter of 2018#Oxybate oncenightly dosing
Narcolepsy2*Program progressing; evaluation of several,$formulation options and technologies5continues as part of oncenightly developmentprocessHematology/OncologyVyxeos Myelodysplastic syndrome4,Preparing for Phase 2 trial with cooperative/'group with planned initiation in secondquarter of 2019Defibrotide/'Prevention of VOD in highrisk patients/'First patient enrolled in Phase 3 trialfollowing HSCT2*in first quarter of 2017; interim analysisplanned in 2019Defibrotide5Prevention of acute Graft versus Host Disease/'First patient enrolled in Phase 2 proof!following allogeneic HSCT1)of concept trial in first quarter of 2018Defibrotide80Transplantassociated thrombotic microangiopathy.&Pivotal Phase 2 trial planned for 2019D
lpdXL@cRdXI=
!"#$%&'() !Asparaginase0!(ALL and other hematological malignancies5!Activities related to development of improved""7"/products, including a recombinant crisantaspase#CombiPlex combinations(# Oncology/hematological disorders7#/Preclinical evaluation of oncology therapeutic$$$combinations%&$'____________________________1()Created by Morningstar Document Research.0)(http://documentresearch.morningstar.com/ocWK#=PF0*8X>
@"))((''
l !P
dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??1!JAZZ PHARMACEUTICALS PUBLIC LIM Waterloo Road Dublin 4 Ireland
SIGNATURES!CONDENSED CONSOLIDATED BALANCE !CONDENSED CONSOLIDATED STATEMEN!CONDENSED CONSOLIDATED STAT (1)!CONDENSED CONSOLIDATED STAT (2)!Adoption of New Accounting Stan!3 Cash and AvailableforSale Sec!3 Cash and AvailableforSale (1)4 Fair Value Measurement!5 Derivative Instruments and He!5 Derivative Instruments an (1)!5 Derivative Instruments an (2)!5 Derivative Instruments an (3)!5 Derivative Instruments an (4)
6 Inventories!7 Goodwill and Intangible Asset!7 Goodwill and Intangible A (1)!7 Goodwill and Intangible A (2)8 Certain Balance Sheet Items8 Certain Balance Sheet I (1)9 Debt
Maturities11 Shareholders Equity11 Shareholders Equity (1)!Accumulated Other Comprehensive!12 Net Income per Ordinary Shar!12 Net Income per Ordinary (1)
13 Revenues13 Revenues (1)13 Revenues (2)!Contract Liabilities Deferred R14 ShareBased Compensation
Share OptionsRestricted Stock Units!Continued Emphasis on Research Continued Emphasis on Rese (1)
Revenues!Research and Development Expens!To continue to grow our businesContractual Obligations!Issuer Purchases of Equity Secu!Issuer Purchases of Equity (1)Base Rent Schedule!CompanyPlanGrant NoticeAgreemen!Additional TermsAcknowledgement!CompanyPlanRSUsAwardGrant Notic!Additional TermsAcknowledge (1)U }6}$ } $}
$}$ }$}$
!
Jazz Pharmaceuticals plc10Q
11/06/2018Results of Operations
Three Months Ended
Increase/
Nine Months Ended
Increase/
September 30,
September 30,~
~
(Decrease)~
~
(Decrease)
Product sales, net~
d
~
~
:
%
~
nU
~
}G
~
R
%'Royalties and contract revenues~
BA~
<~
"
%~
~
~
2 %5Cost of product sales (excluding amortization~
:~
~
%~
~
2/~
2 %of intangible assets)+#Selling, general and administrative~
~
~
f
%~
~
J{~
z % Research and development~
b~
~
"
%~
_
~
~~
r %%Intangible asset amortization~
6~
F~
%~
.u ~
r
~
%Impairment charges   N/A(1)
~
B N/A(1)4,Acquired inprocess research and development ~
N/A(1)
~
"N/A(1)Interest expense, net~
'~
+~
%~
~
*p~
%Foreign exchange loss~
~
"~
%~
P~
n~
V %/'Loss on extinguishment and modification   N/A(1)
~
F N/A(1)of debtIncome tax provision~
R.~
^~
%~
*~
~
: %#Equity in loss of investees~
~
F~
%~
B~
~
%$____________________________1)Created by Morningstar Document Research.Dl}qeYQNqhjglV[`P=CB6* 0 (http://documentresearch.morningstar.com/H=PF0*8X>
@C
l
dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??1!JAZZ PHARMACEUTICALS PUBLIC LIM Waterloo Road Dublin 4 Ireland
SIGNATURES!CONDENSED CONSOLIDATED BALANCE !CONDENSED CONSOLIDATED STATEMEN!CONDENSED CONSOLIDATED STAT (1)!CONDENSED CONSOLIDATED STAT (2)!Adoption of New Accounting Stan!3 Cash and AvailableforSale Sec!3 Cash and AvailableforSale (1)4 Fair Value Measurement!5 Derivative Instruments and He!5 Derivative Instruments an (1)!5 Derivative Instruments an (2)!5 Derivative Instruments an (3)!5 Derivative Instruments an (4)
6 Inventories!7 Goodwill and Intangible Asset!7 Goodwill and Intangible A (1)!7 Goodwill and Intangible A (2)8 Certain Balance Sheet Items8 Certain Balance Sheet I (1)9 Debt
Maturities11 Shareholders Equity11 Shareholders Equity (1)!Accumulated Other Comprehensive!12 Net Income per Ordinary Shar!12 Net Income per Ordinary (1)
13 Revenues13 Revenues (1)13 Revenues (2)!Contract Liabilities Deferred R14 ShareBased Compensation
Share OptionsRestricted Stock Units!Continued Emphasis on Research Continued Emphasis on Rese (1)Results of Operations!Research and Development Expens!To continue to grow our businesContractual Obligations!Issuer Purchases of Equity Secu!Issuer Purchases of Equity (1)Base Rent Schedule!CompanyPlanGrant NoticeAgreemen!Additional TermsAcknowledgement!CompanyPlanRSUsAwardGrant Notic!Additional TermsAcknowledge (1)U }%}$ } $}
$}$ }$}$
Jazz Pharmaceuticals plc10Q
11/06/2018Revenues
Three Months Ended
Increase/
Nine Months Ended
Increase/
September 30,
September 30,~
~
(Decrease)~
~
(Decrease)
Xyrem~
~
~
J
%
~
R>
~
[5
~
J
%Erwinaze/Erwinase~
~
V~
%~
*/ ~
F! ~
%Defitelio/defibrotide~
F5~
~
B
%~
~
~
> %Vyxeos~
H~
ޗ~
%~
F~
ޗ~
%Prialt~
Z~
{~
%~
E~
L~
%
Other~
v;~
^~
n
%~
6~
*~
%Product sales, net~
d~
~
:
%~
nU~
}G~
R %'Royalties and contract revenues~
BA~
<~
"
%~
~
~
2 %Total revenues~
~
>#~
:
%~
UV~
Z)H~
R %$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/:~rf^[=PF0*8X>
@3
l
dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??1!JAZZ PHARMACEUTICALS PUBLIC LIM Waterloo Road Dublin 4 Ireland
SIGNATURES!CONDENSED CONSOLIDATED BALANCE !CONDENSED CONSOLIDATED STATEMEN!CONDENSED CONSOLIDATED STAT (1)!CONDENSED CONSOLIDATED STAT (2)!Adoption of New Accounting Stan!3 Cash and AvailableforSale Sec!3 Cash and AvailableforSale (1)4 Fair Value Measurement!5 Derivative Instruments and He!5 Derivative Instruments an (1)!5 Derivative Instruments an (2)!5 Derivative Instruments an (3)!5 Derivative Instruments an (4)
6 Inventories!7 Goodwill and Intangible Asset!7 Goodwill and Intangible A (1)!7 Goodwill and Intangible A (2)8 Certain Balance Sheet Items8 Certain Balance Sheet I (1)9 Debt
Maturities11 Shareholders Equity11 Shareholders Equity (1)!Accumulated Other Comprehensive!12 Net Income per Ordinary Shar!12 Net Income per Ordinary (1)
13 Revenues13 Revenues (1)13 Revenues (2)!Contract Liabilities Deferred R14 ShareBased Compensation
Share OptionsRestricted Stock Units!Continued Emphasis on Research Continued Emphasis on Rese (1)Results of Operations
Revenues!To continue to grow our businesContractual Obligations!Issuer Purchases of Equity Secu!Issuer Purchases of Equity (1)Base Rent Schedule!CompanyPlanGrant NoticeAgreemen!Additional TermsAcknowledgement!CompanyPlanRSUsAwardGrant Notic!Additional TermsAcknowledge (1)U }}$
Jazz Pharmaceuticals plc10Q
11/06/2018)!Research and Development Expenses
Three Months Ended
Nine Months Ended
September 30,
September 30,~
~
~
~

%Clinical studies and outside services~
~
V
~
M
~
$
Personnel expenses~
~
~
5~
.Milestone expense  ~

Other~
^r~
2T~
j0~
Total~
b~
~
_
~
~$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/24}qeYM:!{A5)=PF0*8X>
@
l )
dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??1!JAZZ PHARMACEUTICALS PUBLIC LIM Waterloo Road Dublin 4 Ireland
SIGNATURES!CONDENSED CONSOLIDATED BALANCE !CONDENSED CONSOLIDATED STATEMEN!CONDENSED CONSOLIDATED STAT (1)!CONDENSED CONSOLIDATED STAT (2)!Adoption of New Accounting Stan!3 Cash and AvailableforSale Sec!3 Cash and AvailableforSale (1)4 Fair Value Measurement!5 Derivative Instruments and He!5 Derivative Instruments an (1)!5 Derivative Instruments an (2)!5 Derivative Instruments an (3)!5 Derivative Instruments an (4)
6 Inventories!7 Goodwill and Intangible Asset!7 Goodwill and Intangible A (1)!7 Goodwill and Intangible A (2)8 Certain Balance Sheet Items8 Certain Balance Sheet I (1)9 Debt
Maturities11 Shareholders Equity11 Shareholders Equity (1)!Accumulated Other Comprehensive!12 Net Income per Ordinary Shar!12 Net Income per Ordinary (1)
13 Revenues13 Revenues (1)13 Revenues (2)!Contract Liabilities Deferred R14 ShareBased Compensation
Share OptionsRestricted Stock Units!Continued Emphasis on Research Continued Emphasis on Rese (1)Results of Operations
Revenues!Research and Development ExpensContractual Obligations!Issuer Purchases of Equity Secu!Issuer Purchases of Equity (1)Base Rent Schedule!CompanyPlanGrant NoticeAgreemen!Additional TermsAcknowledgement!CompanyPlanRSUsAwardGrant Notic!Additional TermsAcknowledge (1)U }1}$
Jazz Pharmaceuticals plc10Q
11/06/2018jbTo continue to grow our business, we will need to commit substantial resources, which could result
Nine Months Ended
September 30,~
~
1
)Net cash provided by operating activities~
z#
~
B
%Net cash used in investing activities~
~
%Net cash used in financing activities~
z~
fx1)Effect of exchange rates on cash and cash~
~
Cequivalents0(Net increase (decrease) in cash and cash~
^~
equivalents$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/4<0$^*D^G=PF0*8X>
@
l 1@
dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??1!JAZZ PHARMACEUTICALS PUBLIC LIM Waterloo Road Dublin 4 Ireland
SIGNATURES!CONDENSED CONSOLIDATED BALANCE !CONDENSED CONSOLIDATED STATEMEN!CONDENSED CONSOLIDATED STAT (1)!CONDENSED CONSOLIDATED STAT (2)!Adoption of New Accounting Stan!3 Cash and AvailableforSale Sec!3 Cash and AvailableforSale (1)4 Fair Value Measurement!5 Derivative Instruments and He!5 Derivative Instruments an (1)!5 Derivative Instruments an (2)!5 Derivative Instruments an (3)!5 Derivative Instruments an (4)
6 Inventories!7 Goodwill and Intangible Asset!7 Goodwill and Intangible A (1)!7 Goodwill and Intangible A (2)8 Certain Balance Sheet Items8 Certain Balance Sheet I (1)9 Debt
Maturities11 Shareholders Equity11 Shareholders Equity (1)!Accumulated Other Comprehensive!12 Net Income per Ordinary Shar!12 Net Income per Ordinary (1)
13 Revenues13 Revenues (1)13 Revenues (2)!Contract Liabilities Deferred R14 ShareBased Compensation
Share OptionsRestricted Stock Units!Continued Emphasis on Research Continued Emphasis on Rese (1)Results of Operations
Revenues!Research and Development Expens!To continue to grow our busines!Issuer Purchases of Equity Secu!Issuer Purchases of Equity (1)Base Rent Schedule!CompanyPlanGrant NoticeAgreemen!Additional TermsAcknowledgement!CompanyPlanRSUsAwardGrant Notic!Additional TermsAcknowledge (1)U }0}$
Jazz Pharmaceuticals plc10Q
11/06/2018Contractual Obligations
Payments Due by Period#Contractual Obligations (1)
Total Less than 13 Years
35 Years More than1 Year
5 years
Term loan  principal~
>(
~
~
V
~
!"
$
Term loan  interest (2)~
~
W~
V{~
%Exchangeable Senior Notes  principal~
0F ~
b#
~
b#0(Exchangeable Senior Notes  interest (3)~
!~
:/~
v^~
~
Ɔ.&Revolving credit facility  commitment~
(~
b?~
~~
j fee (4)%Commitment to equity method investees~
r\~
bm~
~
R *"Purchase and other obligations (5)~
L ~
jW~
m~
B~
z'Operating lease obligations (6)~
~
~
~
r~
&Facility lease obligations (7)~
z~
~
~
~
r
Total~
L~
Ω ~
R2~
N*~
2,$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/>0{ocWg9}'A^Ki
=PF0*8X>
@=
l R
dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??1!JAZZ PHARMACEUTICALS PUBLIC LIM Waterloo Road Dublin 4 Ireland
SIGNATURES!CONDENSED CONSOLIDATED BALANCE !CONDENSED CONSOLIDATED STATEMEN!CONDENSED CONSOLIDATED STAT (1)!CONDENSED CONSOLIDATED STAT (2)!Adoption of New Accounting Stan!3 Cash and AvailableforSale Sec!3 Cash and AvailableforSale (1)4 Fair Value Measurement!5 Derivative Instruments and He!5 Derivative Instruments an (1)!5 Derivative Instruments an (2)!5 Derivative Instruments an (3)!5 Derivative Instruments an (4)
6 Inventories!7 Goodwill and Intangible Asset!7 Goodwill and Intangible A (1)!7 Goodwill and Intangible A (2)8 Certain Balance Sheet Items8 Certain Balance Sheet I (1)9 Debt
Maturities11 Shareholders Equity11 Shareholders Equity (1)!Accumulated Other Comprehensive!12 Net Income per Ordinary Shar!12 Net Income per Ordinary (1)
13 Revenues13 Revenues (1)13 Revenues (2)!Contract Liabilities Deferred R14 ShareBased Compensation
Share OptionsRestricted Stock Units!Continued Emphasis on Research Continued Emphasis on Rese (1)Results of Operations
Revenues!Research and Development Expens!To continue to grow our businesContractual Obligations!Issuer Purchases of Equity (1)Base Rent Schedule!CompanyPlanGrant NoticeAgreemen!Additional TermsAcknowledgement!CompanyPlanRSUsAwardGrant Notic!Additional TermsAcknowledge (1)U }'}}$ }}
$
Jazz Pharmaceuticals plc10Q
11/06/2018%Issuer Purchases of Equity Securities
,
$Total Number of Shares Purchased (1)
(
Average Price Paid per Share (2)
0
(Total Number of Shares Purchased as Part

%Maximum Number (or Approximate Dollar/'of Publicly Announced Plans or Programs
2*Value) of Shares that May Yet Be Purchased~
'Under the Plans or Programs (4)
July 1  July 31, 2018

$

~
R
"August 1  August 31, 2018~
fffffe@~
~
KZ
( September 1  September 30, 2018~
2d@~
2
~
5
Total~
2q=
ףe@~
2
$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/0ymaUI6ymE=PF0*8X>
@
l Fdno
dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??1!JAZZ PHARMACEUTICALS PUBLIC LIM Waterloo Road Dublin 4 Ireland
SIGNATURES!CONDENSED CONSOLIDATED BALANCE !CONDENSED CONSOLIDATED STATEMEN!CONDENSED CONSOLIDATED STAT (1)!CONDENSED CONSOLIDATED STAT (2)!Adoption of New Accounting Stan!3 Cash and AvailableforSale Sec!3 Cash and AvailableforSale (1)4 Fair Value Measurement!5 Derivative Instruments and He!5 Derivative Instruments an (1)!5 Derivative Instruments an (2)!5 Derivative Instruments an (3)!5 Derivative Instruments an (4)
6 Inventories!7 Goodwill and Intangible Asset!7 Goodwill and Intangible A (1)!7 Goodwill and Intangible A (2)8 Certain Balance Sheet Items8 Certain Balance Sheet I (1)9 Debt
Maturities11 Shareholders Equity11 Shareholders Equity (1)!Accumulated Other Comprehensive!12 Net Income per Ordinary Shar!12 Net Income per Ordinary (1)
13 Revenues13 Revenues (1)13 Revenues (2)!Contract Liabilities Deferred R14 ShareBased Compensation
Share OptionsRestricted Stock Units!Continued Emphasis on Research Continued Emphasis on Rese (1)Results of Operations
Revenues!Research and Development Expens!To continue to grow our businesContractual Obligations!Issuer Purchases of Equity SecuBase Rent Schedule!CompanyPlanGrant NoticeAgreemen!Additional TermsAcknowledgement!CompanyPlanRSUsAwardGrant Notic!Additional TermsAcknowledge (1)U }I }6
F
Jazz Pharmaceuticals plc10Q
11/06/2018%Issuer Purchases of Equity Securities
4.4A/
'Indenture, dated as of August 23, 2017,1)among Jazz Pharmaceuticals Public Limited/'Company, Jazz Investments I Limited and
4
,U.S. Bank National Association (incorporated2*herein by reference to Exhibit 4.1 in Jazz,$Pharmaceuticals plc?s Current Report3+on Form 8K (File No. 001033500), as filed)!with the SEC on August 23, 2017).4.4B.&Form of 1.50% Exchangeable Senior Note2*due 2024 (incorporated herein by reference.&to Exhibit 4.2 in Jazz Pharmaceuticals2*plc?s Current Report on Form 8K (File No.4,001033500), as filed with the SEC on August23, 2017) .333333$@4,Second Amendment, dated as of July 26, 2018,0(to Commercial Lease, dated as of January57, 2015, by and between The Board of Trustees0(of the Leland Stanford Junior University5and Jazz Pharmaceuticals, Inc., as previously0(amended by the First Amendment to Lease,%dated as of January 29, 2018.
10.2+0(Form of NonU.S. Option Grant Notice andDlymaUI1n*i0n,{;q1 !"#$%&'()*+,./0123456789:;<=>? 0 (NonU.S. Option Agreement under the Jazz!0!(Pharmaceuticals plc Amended and Restated"/"'2007 NonEmployee Directors Stock Award#
#Plan.
$10.3+.$&Form of NonU.S. Restricted Stock Unit%2%*Award Grant Notice and NonU.S. Restricted&1&)Stock Unit Award Agreement under the Jazz'0'(Pharmaceuticals plc Amended and Restated(/('2007 NonEmployee Directors Stock Award)
)Plan.*?@0*(Certification of Chief Executive Officer+1+)pursuant to Rules 13a14(a) and 15d14(a),1,)promulgated under the Securities Exchange Act of 1934, as amended..333333?@0.(Certification of Chief Financial Officer/1/)pursuant to Rules 13a14(a) and 15d14(a)010)promulgated under the Securities Exchange1 1Act of 1934, as amended.
232.1*12)Certifications of Chief Executive Officer3/3'and Chief Financial Officer pursuant to434+18 U.S.C. Section 1350, as adopted pursuant505(to Section 906 of the SarbanesOxley Act66of 2002.7101.INS7XBRL Instance Document8101.SCH/8'XBRL Taxonomy Extension Schema Document9101.CAL49,XBRL Taxonomy Extension Calculation Linkbase::Document;101.DEF3;+XBRL Taxonomy Extension Definition Linkbase<<Document=101.LAB/='XBRL Taxonomy Extension Labels Linkbase>>Document?101.PRE,?$XBRL Taxonomy Extension PresentationD lA$^;CM
u/zZ@ABCDE@@Linkbase DocumentAB$C____________________________1D)Created by Morningstar Document Research.0E(http://documentresearch.morningstar.com/Jd=PF0*8X>
@EEDDCC
l !
dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??1!JAZZ PHARMACEUTICALS PUBLIC LIM Waterloo Road Dublin 4 Ireland
SIGNATURES!CONDENSED CONSOLIDATED BALANCE !CONDENSED CONSOLIDATED STATEMEN!CONDENSED CONSOLIDATED STAT (1)!CONDENSED CONSOLIDATED STAT (2)!Adoption of New Accounting Stan!3 Cash and AvailableforSale Sec!3 Cash and AvailableforSale (1)4 Fair Value Measurement!5 Derivative Instruments and He!5 Derivative Instruments an (1)!5 Derivative Instruments an (2)!5 Derivative Instruments an (3)!5 Derivative Instruments an (4)
6 Inventories!7 Goodwill and Intangible Asset!7 Goodwill and Intangible A (1)!7 Goodwill and Intangible A (2)8 Certain Balance Sheet Items8 Certain Balance Sheet I (1)9 Debt
Maturities11 Shareholders Equity11 Shareholders Equity (1)!Accumulated Other Comprehensive!12 Net Income per Ordinary Shar!12 Net Income per Ordinary (1)
13 Revenues13 Revenues (1)13 Revenues (2)!Contract Liabilities Deferred R14 ShareBased Compensation
Share OptionsRestricted Stock Units!Continued Emphasis on Research Continued Emphasis on Rese (1)Results of Operations
Revenues!Research and Development Expens!To continue to grow our businesContractual Obligations!Issuer Purchases of Equity Secu!Issuer Purchases of Equity (1)!CompanyPlanGrant NoticeAgreemen!Additional TermsAcknowledgement!CompanyPlanRSUsAwardGrant Notic!Additional TermsAcknowledge (1)U }a/}1}a
!
Jazz Pharmaceuticals plc10Q
11/06/2018Base Rent Schedule
Period During1
)Monthly Base Rent per sq. ft. of Rentable
Monthly Base Rent
Lease TermArea10/15/2017  1/14/2018~
~
(due to free rent)
(due to free rent)1/15/2018  2/28/2018@~
!3/1/201810/31/2018333333@\ A/'($0.05 per square foot increase begins)11/1/2018  10/31/2019zG@(\4!A11/1/2019  10/31/2020(\@{ʸ!A11/1/2020  10/31/2021=
ףp=@(\@"A11/1/2021  10/31/2022@3333"A11/1/2022  10/31/2023Q@y]#A11/1/2023  10/31/2024Q@Hz3#A11/1/2024  10/31/2025RQ@333b$A11/1/2025  10/31/2026Q@{*)%A11/1/2026  10/31/2027(\@Q%A11/1/2027  10/31/2028ףp=
@Hzs&A11/1/2028  10/14/2029Q@'A$____________________________1)Created by Morningstar Document Research.Dlth\8i!j$R:h\P 0 (http://documentresearch.morningstar.com/H=PF0*8X>
@
l
dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??1!JAZZ PHARMACEUTICALS PUBLIC LIM Waterloo Road Dublin 4 Ireland
SIGNATURES!CONDENSED CONSOLIDATED BALANCE !CONDENSED CONSOLIDATED STATEMEN!CONDENSED CONSOLIDATED STAT (1)!CONDENSED CONSOLIDATED STAT (2)!Adoption of New Accounting Stan!3 Cash and AvailableforSale Sec!3 Cash and AvailableforSale (1)4 Fair Value Measurement!5 Derivative Instruments and He!5 Derivative Instruments an (1)!5 Derivative Instruments an (2)!5 Derivative Instruments an (3)!5 Derivative Instruments an (4)
6 Inventories!7 Goodwill and Intangible Asset!7 Goodwill and Intangible A (1)!7 Goodwill and Intangible A (2)8 Certain Balance Sheet Items8 Certain Balance Sheet I (1)9 Debt
Maturities11 Shareholders Equity11 Shareholders Equity (1)!Accumulated Other Comprehensive!12 Net Income per Ordinary Shar!12 Net Income per Ordinary (1)
13 Revenues13 Revenues (1)13 Revenues (2)!Contract Liabilities Deferred R14 ShareBased Compensation
Share OptionsRestricted Stock Units!Continued Emphasis on Research Continued Emphasis on Rese (1)Results of Operations
Revenues!Research and Development Expens!To continue to grow our businesContractual Obligations!Issuer Purchases of Equity Secu!Issuer Purchases of Equity (1)Base Rent Schedule!Additional TermsAcknowledgement!CompanyPlanRSUsAwardGrant Notic!Additional TermsAcknowledge (1)U }U5}$
Jazz Pharmaceuticals plc10Q
11/06/2018( CompanyPlanGrant NoticeAgreement
Optionholder:
Option #:Date of Grant:"
Vesting Commencement Date:
4,Number of Ordinary Shares Subject to Option:,$Exercise Price (Per Ordinary Share):Total Exercise Price:Expiration Date:$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/2~rfZN6T=PF0*8X>
@
l
dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??1!JAZZ PHARMACEUTICALS PUBLIC LIM Waterloo Road Dublin 4 Ireland
SIGNATURES!CONDENSED CONSOLIDATED BALANCE !CONDENSED CONSOLIDATED STATEMEN!CONDENSED CONSOLIDATED STAT (1)!CONDENSED CONSOLIDATED STAT (2)!Adoption of New Accounting Stan!3 Cash and AvailableforSale Sec!3 Cash and AvailableforSale (1)4 Fair Value Measurement!5 Derivative Instruments and He!5 Derivative Instruments an (1)!5 Derivative Instruments an (2)!5 Derivative Instruments an (3)!5 Derivative Instruments an (4)
6 Inventories!7 Goodwill and Intangible Asset!7 Goodwill and Intangible A (1)!7 Goodwill and Intangible A (2)8 Certain Balance Sheet Items8 Certain Balance Sheet I (1)9 Debt
Maturities11 Shareholders Equity11 Shareholders Equity (1)!Accumulated Other Comprehensive!12 Net Income per Ordinary Shar!12 Net Income per Ordinary (1)
13 Revenues13 Revenues (1)13 Revenues (2)!Contract Liabilities Deferred R14 ShareBased Compensation
Share OptionsRestricted Stock Units!Continued Emphasis on Research Continued Emphasis on Rese (1)Results of Operations
Revenues!Research and Development Expens!To continue to grow our businesContractual Obligations!Issuer Purchases of Equity Secu!Issuer Purchases of Equity (1)Base Rent Schedule!CompanyPlanGrant NoticeAgreemen!CompanyPlanRSUsAwardGrant Notic!Additional TermsAcknowledge (1)U }}}$ }}$
Jazz Pharmaceuticals plc10Q
11/06/2018*"Additional Terms/Acknowledgements:
JAZZ PHARMACEUTICALS PLC
OPTIONHOLDER
By:
Signature SignatureTitle:
Date:
Date:$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/2pdXL};wk_7=PF0*8X>
@2
l d
dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??1!JAZZ PHARMACEUTICALS PUBLIC LIM Waterloo Road Dublin 4 Ireland
SIGNATURES!CONDENSED CONSOLIDATED BALANCE !CONDENSED CONSOLIDATED STATEMEN!CONDENSED CONSOLIDATED STAT (1)!CONDENSED CONSOLIDATED STAT (2)!Adoption of New Accounting Stan!3 Cash and AvailableforSale Sec!3 Cash and AvailableforSale (1)4 Fair Value Measurement!5 Derivative Instruments and He!5 Derivative Instruments an (1)!5 Derivative Instruments an (2)!5 Derivative Instruments an (3)!5 Derivative Instruments an (4)
6 Inventories!7 Goodwill and Intangible Asset!7 Goodwill and Intangible A (1)!7 Goodwill and Intangible A (2)8 Certain Balance Sheet Items8 Certain Balance Sheet I (1)9 Debt
Maturities11 Shareholders Equity11 Shareholders Equity (1)!Accumulated Other Comprehensive!12 Net Income per Ordinary Shar!12 Net Income per Ordinary (1)
13 Revenues13 Revenues (1)13 Revenues (2)!Contract Liabilities Deferred R14 ShareBased Compensation
Share OptionsRestricted Stock Units!Continued Emphasis on Research Continued Emphasis on Rese (1)Results of Operations
Revenues!Research and Development Expens!To continue to grow our businesContractual Obligations!Issuer Purchases of Equity Secu!Issuer Purchases of Equity (1)Base Rent Schedule!CompanyPlanGrant NoticeAgreemen!Additional TermsAcknowledgement!Additional TermsAcknowledge (1)U }'}6
Jazz Pharmaceuticals plc10Q
11/06/20181)CompanyPlanRSUsAwardGrant NoticeAgreement
Participant:
RSU #:Date of Grant:"
Vesting Commencement Date:
( Number of RSUs Subject to Award:Consideration:Participant's Services5(payment of par value of newly issued shares)$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/0ui]QE [=PF0*8X>
@
l a
dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??1!JAZZ PHARMACEUTICALS PUBLIC LIM Waterloo Road Dublin 4 Ireland
SIGNATURES!CONDENSED CONSOLIDATED BALANCE !CONDENSED CONSOLIDATED STATEMEN!CONDENSED CONSOLIDATED STAT (1)!CONDENSED CONSOLIDATED STAT (2)!Adoption of New Accounting Stan!3 Cash and AvailableforSale Sec!3 Cash and AvailableforSale (1)4 Fair Value Measurement!5 Derivative Instruments and He!5 Derivative Instruments an (1)!5 Derivative Instruments an (2)!5 Derivative Instruments an (3)!5 Derivative Instruments an (4)
6 Inventories!7 Goodwill and Intangible Asset!7 Goodwill and Intangible A (1)!7 Goodwill and Intangible A (2)8 Certain Balance Sheet Items8 Certain Balance Sheet I (1)9 Debt
Maturities11 Shareholders Equity11 Shareholders Equity (1)!Accumulated Other Comprehensive!12 Net Income per Ordinary Shar!12 Net Income per Ordinary (1)
13 Revenues13 Revenues (1)13 Revenues (2)!Contract Liabilities Deferred R14 ShareBased Compensation
Share OptionsRestricted Stock Units!Continued Emphasis on Research Continued Emphasis on Rese (1)Results of Operations
Revenues!Research and Development Expens!To continue to grow our businesContractual Obligations!Issuer Purchases of Equity Secu!Issuer Purchases of Equity (1)Base Rent Schedule!CompanyPlanGrant NoticeAgreemen!Additional TermsAcknowledgement!CompanyPlanRSUsAwardGrant NoticU }}}$ }}$
Jazz Pharmaceuticals plc10Q
11/06/2018*"Additional Terms/Acknowledgements:
JAZZ PHARMACEUTICALS PLC
PARTICIPANT
By:
Signature SignatureTitle:
Date:
Date:$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/2pdXL~
@2
Root Entry FBook
!"#$%&'()*+,./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{}~
!"#$%&'()*+,./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{}~